NZ617303B2 - Methods of improving vaccine immunogenicity - Google Patents
Methods of improving vaccine immunogenicity Download PDFInfo
- Publication number
- NZ617303B2 NZ617303B2 NZ617303A NZ61730312A NZ617303B2 NZ 617303 B2 NZ617303 B2 NZ 617303B2 NZ 617303 A NZ617303 A NZ 617303A NZ 61730312 A NZ61730312 A NZ 61730312A NZ 617303 B2 NZ617303 B2 NZ 617303B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antigen
- antibody
- compound
- cells
- epitope
- Prior art date
Links
- 229960005486 vaccines Drugs 0.000 title description 91
- 239000000427 antigen Substances 0.000 claims abstract description 146
- 108091007172 antigens Proteins 0.000 claims abstract description 146
- 102000038129 antigens Human genes 0.000 claims abstract description 146
- 150000001875 compounds Chemical class 0.000 claims abstract description 77
- 150000001413 amino acids Chemical class 0.000 claims abstract description 34
- 241000991587 Enterovirus C Species 0.000 claims abstract description 10
- 102000004965 antibodies Human genes 0.000 claims description 203
- 108090001123 antibodies Proteins 0.000 claims description 203
- 150000007523 nucleic acids Chemical class 0.000 claims description 80
- 239000000203 mixture Substances 0.000 claims description 66
- 108020004707 nucleic acids Proteins 0.000 claims description 55
- 241000282414 Homo sapiens Species 0.000 claims description 50
- 230000003053 immunization Effects 0.000 claims description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 230000028993 immune response Effects 0.000 claims description 35
- 238000002649 immunization Methods 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 101700016449 GLA Proteins 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 22
- 230000000240 adjuvant Effects 0.000 claims description 22
- 230000002458 infectious Effects 0.000 claims description 21
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 20
- 102000004873 Nucleocapsid Proteins Human genes 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 20
- 230000003612 virological Effects 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000021615 conjugation Effects 0.000 claims description 9
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 7
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 7
- 230000001580 bacterial Effects 0.000 claims description 7
- 230000003000 nontoxic Effects 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000001225 therapeutic Effects 0.000 claims description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 200000000003 influenza A Diseases 0.000 claims description 6
- 230000002538 fungal Effects 0.000 claims description 5
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 claims description 3
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 claims description 3
- QIGJYVCQYDKYDW-SDOYDPJRSA-N Galactose-α-1,3-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-SDOYDPJRSA-N 0.000 claims description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000069 prophylaxis Effects 0.000 claims description 3
- 150000004676 glycans Polymers 0.000 claims description 2
- 230000003071 parasitic Effects 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 150000004804 polysaccharides Polymers 0.000 claims description 2
- 210000004027 cells Anatomy 0.000 description 157
- 229920001850 Nucleic acid sequence Polymers 0.000 description 74
- 230000004044 response Effects 0.000 description 67
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 66
- 235000018102 proteins Nutrition 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 40
- 230000027455 binding Effects 0.000 description 35
- 229920002477 rna polymer Polymers 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 33
- 230000002708 enhancing Effects 0.000 description 33
- 238000000034 method Methods 0.000 description 33
- 229920001184 polypeptide Polymers 0.000 description 27
- 239000000126 substance Substances 0.000 description 23
- 206010022000 Influenza Diseases 0.000 description 21
- 210000001744 T-Lymphocytes Anatomy 0.000 description 21
- 230000035897 transcription Effects 0.000 description 21
- 208000006572 Human Influenza Diseases 0.000 description 20
- 108010045030 monoclonal antibodies Proteins 0.000 description 20
- 238000002255 vaccination Methods 0.000 description 20
- 108020004511 Recombinant DNA Proteins 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 102000005614 monoclonal antibodies Human genes 0.000 description 19
- 229920001405 Coding region Polymers 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 230000001105 regulatory Effects 0.000 description 18
- 125000005647 linker group Chemical group 0.000 description 17
- 210000002966 Serum Anatomy 0.000 description 16
- -1 diabodies Proteins 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 239000000969 carrier Substances 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 15
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 14
- 210000004408 Hybridomas Anatomy 0.000 description 13
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 229960000060 monoclonal antibodies Drugs 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 230000035693 Fab Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 230000024932 T cell mediated immunity Effects 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 102000018358 Immunoglobulins Human genes 0.000 description 11
- 108060003951 Immunoglobulins Proteins 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 10
- 210000000987 Immune System Anatomy 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- 229940037003 alum Drugs 0.000 description 10
- 108091006028 chimera Proteins 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 201000000050 myeloid neoplasm Diseases 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 210000003719 B-Lymphocytes Anatomy 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 230000001413 cellular Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000028996 humoral immune response Effects 0.000 description 9
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 9
- 239000002609 media Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 230000035492 administration Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000003834 intracellular Effects 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001519 tissues Anatomy 0.000 description 8
- 210000000628 Antibody-Producing Cells Anatomy 0.000 description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 210000004681 Ovum Anatomy 0.000 description 7
- 208000000474 Poliomyelitis Diseases 0.000 description 7
- 230000033289 adaptive immune response Effects 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000000890 antigenic Effects 0.000 description 7
- 238000002869 basic local alignment search tool Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001965 increased Effects 0.000 description 7
- 230000001131 transforming Effects 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 230000001402 polyadenylating Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 229920002676 Complementary DNA Polymers 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 210000004698 Lymphocytes Anatomy 0.000 description 5
- 229940092253 Ovalbumin Drugs 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 239000004698 Polyethylene (PE) Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000023298 conjugation with cellular fusion Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 230000002068 genetic Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 238000010212 intracellular staining Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000001806 memory B lymphocyte Anatomy 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000001717 pathogenic Effects 0.000 description 5
- 244000052769 pathogens Species 0.000 description 5
- 108091008117 polyclonal antibodies Proteins 0.000 description 5
- 230000002335 preservative Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002633 protecting Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- KYHPMCZXXRPOKS-ZJWYQBPBSA-N 3,7-dihydropurin-6-one;2-hydrazinyl-1H-pteridin-4-one;1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 KYHPMCZXXRPOKS-ZJWYQBPBSA-N 0.000 description 4
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- 102000033147 ERVK-25 Human genes 0.000 description 4
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- 208000002672 Hepatitis B Diseases 0.000 description 4
- 102000011931 Nucleoproteins Human genes 0.000 description 4
- 108010061100 Nucleoproteins Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth media Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- HVLGNZWAUGQTTF-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)butanedioic acid;ethane-1,2-diol Chemical compound OCCO.OC(=O)CC(C(O)=O)N1C(=O)CCC1=O.OC(=O)CC(C(O)=O)N1C(=O)CCC1=O HVLGNZWAUGQTTF-UHFFFAOYSA-N 0.000 description 3
- 230000003844 B-cell-activation Effects 0.000 description 3
- VYLDEYYOISNGST-UHFFFAOYSA-N Bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102000018251 EC 2.4.2.8 Human genes 0.000 description 3
- 108010091358 EC 2.4.2.8 Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 208000006454 Hepatitis Diseases 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 3
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 108010078762 Protein Precursors Proteins 0.000 description 3
- 102000014961 Protein Precursors Human genes 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 210000000952 Spleen Anatomy 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 231100000765 Toxin Toxicity 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 244000052616 bacterial pathogens Species 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002101 lytic Effects 0.000 description 3
- 210000004962 mammalian cells Anatomy 0.000 description 3
- 108091005593 modified peptides Proteins 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 108020003112 toxins Proteins 0.000 description 3
- 230000005026 transcription initiation Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- YAMUFBLWGFFICM-PTGWMXDISA-N 1-O-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-N 0.000 description 2
- MBDUIEKYVPVZJH-UHFFFAOYSA-N 1-ethylsulfonylethane Chemical compound CCS(=O)(=O)CC MBDUIEKYVPVZJH-UHFFFAOYSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 241000432074 Adeno-associated virus Species 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229960001230 Asparagine Drugs 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N Bute hydrocarbon Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229960004926 Chlorobutanol Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000001106 Chromosomes, Artificial, Yeast Anatomy 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N Disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 210000000887 Face Anatomy 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006822 Human Serum Albumin Proteins 0.000 description 2
- 229920002459 Intron Polymers 0.000 description 2
- 108020004391 Introns Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 210000001165 Lymph Nodes Anatomy 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 210000002850 Nasal Mucosa Anatomy 0.000 description 2
- 229920000272 Oligonucleotide Polymers 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229940055729 Papain Drugs 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- 210000003200 Peritoneal Cavity Anatomy 0.000 description 2
- 210000004011 Plasma Cells Anatomy 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000007759 RPMI Media 1640 Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000724205 Rice stripe tenuivirus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 208000001203 Smallpox Diseases 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108091008153 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 208000004441 Taeniasis Diseases 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 208000001877 Whooping Cough Diseases 0.000 description 2
- 230000003044 adaptive Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 2
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 230000001024 immunotherapeutic Effects 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000011031 large scale production Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 201000005702 pertussis Diseases 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001888 polyacrylic acid Polymers 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 230000003393 splenic Effects 0.000 description 2
- 230000004936 stimulating Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000002103 transcriptional Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- PYAFUXYGTYWWBP-UHFFFAOYSA-N 19-methoxynonadecane-1,2,3-triol Chemical compound COCCCCCCCCCCCCCCCCC(O)C(O)CO PYAFUXYGTYWWBP-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 description 1
- SYEKJCKNTHYWOJ-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)-2-sulfobutanedioic acid;ethane-1,2-diol Chemical compound OCCO.OC(=O)CC(S(O)(=O)=O)(C(O)=O)N1C(=O)CCC1=O.OC(=O)CC(S(O)(=O)=O)(C(O)=O)N1C(=O)CCC1=O SYEKJCKNTHYWOJ-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101700033661 ACTB Proteins 0.000 description 1
- 102100011550 ACTB Human genes 0.000 description 1
- 101710032514 ACTI Proteins 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 241000224422 Acanthamoeba Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 102000009914 Adenosine deaminases Human genes 0.000 description 1
- 108091022188 Adenosine deaminases Proteins 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 208000006778 Allergic Bronchopulmonary Aspergillosis Diseases 0.000 description 1
- 201000004560 Alpers syndrome Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 241000269328 Amphibia Species 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 206010003486 Aspergillus infection Diseases 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- 206010004018 Bacterial infectious disease Diseases 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 230000035639 Blood Levels Effects 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infection Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000003732 Cat-Scratch Disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 201000003884 Chagas disease Diseases 0.000 description 1
- 108010035563 Chloramphenicol O-Acetyltransferase Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 206010009344 Clonorchiasis Diseases 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 208000009802 Colorado Tick Fever Diseases 0.000 description 1
- 108009000280 Complement Activation Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 229940095074 Cyclic AMP Drugs 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229960000633 Dextran Sulfate Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010013023 Diphtheria Diseases 0.000 description 1
- 206010013029 Diphyllobothriasis Diseases 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 208000008576 Dracunculiasis Diseases 0.000 description 1
- 102000013009 EC 2.7.1.40 Human genes 0.000 description 1
- 108020005115 EC 2.7.1.40 Proteins 0.000 description 1
- 206010014071 Ebola disease Diseases 0.000 description 1
- 206010014096 Echinococciasis Diseases 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 206010014881 Enterobiasis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 229920001272 Exogenous DNA Polymers 0.000 description 1
- 102100015543 FCGR2B Human genes 0.000 description 1
- 208000006275 Fascioliasis Diseases 0.000 description 1
- 206010016235 Fasciolopsiasis Diseases 0.000 description 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017918 Gastroenteritis viral Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 208000000807 Gnathostomiasis Diseases 0.000 description 1
- 208000001786 Gonorrhea Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000007514 Herpes Zoster Diseases 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000007188 Hymenolepiasis Diseases 0.000 description 1
- 241000244166 Hymenolepis diminuta Species 0.000 description 1
- 241001464384 Hymenolepis nana Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 206010023497 Kuru Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 208000009874 Lice Infestations Diseases 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010025169 Lyme disease Diseases 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 208000006123 Myiasis Diseases 0.000 description 1
- 241000224438 Naegleria fowleri Species 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 240000008962 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000187678 Nocardia asteroides Species 0.000 description 1
- 241001503696 Nocardia brasiliensis Species 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 208000002042 Onchocerciasis Diseases 0.000 description 1
- 229940043515 Other immunoglobulins in ATC Drugs 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 102000033170 PRNP Human genes 0.000 description 1
- 101710024107 PRNP Proteins 0.000 description 1
- 208000006551 Parasitic Disease Diseases 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N Pathocidin Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 102100011271 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 241000254064 Photinus pyralis Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003055 Prion Disease Diseases 0.000 description 1
- 102000030002 Prion Proteins Human genes 0.000 description 1
- 108091000054 Prion Proteins Proteins 0.000 description 1
- 240000002799 Prunus avium Species 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 206010065214 Pyelonephritis fungal Diseases 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N Pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010039207 Rocky mountain spotted fever Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 208000005687 Scabies Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039587 Scarlet fever Diseases 0.000 description 1
- 101710043164 Segment-4 Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010040550 Shigella infection Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 206010041925 Staphylococcal infection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006379 Syphilis Diseases 0.000 description 1
- 210000000662 T-Lymphocyte Subsets Anatomy 0.000 description 1
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 1
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- 206010044269 Toxocariasis Diseases 0.000 description 1
- 206010044325 Trachoma Diseases 0.000 description 1
- 241000390203 Trachoma Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 Triacetin Drugs 0.000 description 1
- 208000003982 Trichinellosis Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 208000009920 Trichuriasis Diseases 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N Tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 229940035670 Tuftsin Drugs 0.000 description 1
- 206010045146 Tularaemia Diseases 0.000 description 1
- 206010061393 Typhus Diseases 0.000 description 1
- 206010046577 Urinary tract infection Diseases 0.000 description 1
- 101700038759 VP1 Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 210000003501 Vero Cells Anatomy 0.000 description 1
- 208000009421 Viral Pneumonia Diseases 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- GOWLTLODGKPXMN-MEKRSRHXSA-N [(3S)-1-[[(2R,3R,4R,5S,6R)-2-[[(2R,3S,4R,5R,6R)-3,4-dihydroxy-5-[[(3R)-3-hydroxytetradecanoyl]amino]-6-phosphonooxyoxan-2-yl]methoxy]-4-hydroxy-6-(hydroxymethyl)-5-phosphonooxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] dodecanoate Chemical compound O1[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1CO[C@H]1[C@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 GOWLTLODGKPXMN-MEKRSRHXSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004931 aggregating Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000007961 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent Effects 0.000 description 1
- 230000005164 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000002909 aspergillosis Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000004927 campylobacteriosis Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 101700018328 ccdB Proteins 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 201000006082 chickenpox Diseases 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 230000001886 ciliary Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 201000009230 common cold Diseases 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 201000007336 cryptococcosis Diseases 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000000077 cysticercosis Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 201000008167 cystoisosporiasis Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 201000002949 dengue disease Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical class O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 201000006353 filariasis Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010358 genetic engineering technique Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 230000030414 genetic transfer Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 201000000128 gnathomiasis Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000006215 hand, foot and mouth disease Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 101700005460 hemA Proteins 0.000 description 1
- 108060003552 hemocyanin family Proteins 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N hexadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000002563 histoplasmosis Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000032226 immune complex clearance Effects 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulators Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000009085 invasive aspergillosis Diseases 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000000873 masking Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 201000005505 measles Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000004015 melioidosis Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000001198 metagonimiasis Diseases 0.000 description 1
- MBAXWTVHCRPVFW-UHFFFAOYSA-N methyl 3-[(3-imino-3-methoxypropyl)disulfanyl]propanimidate Chemical compound COC(=N)CCSSCCC(=N)OC MBAXWTVHCRPVFW-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000007758 minimum essential media Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N n-pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000003571 opsonizing Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000090 phagocyte Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 201000009800 pulmonary aspergilloma Diseases 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000002707 regulatory B cell Anatomy 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 230000000754 repressing Effects 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 231100000202 sensitizing Toxicity 0.000 description 1
- 102000026930 sequence-specific DNA binding proteins Human genes 0.000 description 1
- 108091007746 sequence-specific DNA binding proteins Proteins 0.000 description 1
- 201000003176 severe acute respiratory syndrome Diseases 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000001743 silencing Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N stearylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 201000005485 toxoplasmosis Diseases 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 230000002463 transducing Effects 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 108010042685 trinitrophenyl keyhole limpet hemocyanin Proteins 0.000 description 1
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000021037 unidirectional conjugation Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 201000006266 variola major Diseases 0.000 description 1
- 201000000627 variola minor Diseases 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32041—Use of virus, viral particle or viral elements as a vector
- C12N2770/32042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Disclosed is a compound comprising at least one antigen directly covalently bound to an antibody-recognition epitope (ARE), wherein the ARE is a VP-1 epitope of polio virus of about 11-28 amino acids in length comprising IPALTAVETGA (SEQ ID NO: 1).
Description
METHODS OF IMPROVING VACCINE IMMUNOGENICITY
PRIORITY OF INVENTION
This application claims priority to United States Provisional Application
Number 61/471,553 that was filed on April 4, 2011. The entire content of this
provisional application is hereby incorporated herein by reference.
BACKGROUND OF THE INVENTION
The immune system is quite complex and includes many different pathways
for an organism to fight infectious pathogens and cancer cells. In general, the
immune system is viewed as being able to mount a humoral immune response (HIR)
and/or a cell-mediated immune response (CMI). The HIR involves the production
and secretion of antibodies produced in the cells of the B lymphocyte lineage (B-
cells). Secreted antibodies bind to antigens on the surfaces of invading microbes
(such as viruses or bacteria). The antibody-bound antigens are then destroyed by
various cells in the immune system. Humoral immunity also refers to antibody
production and the accessory processes that accompany it. It also refers to the
effector functions of antibody, which include pathogen and toxin neutralization,
classical complement activation, and opsonin promotion of phagocytosis and
pathogen elimination.
The second type of immune response is cell-mediated immunity (CMI).
CMI is an immune response that does not involve antibodies or complement but
instead involves the activation of various immune cells, such as macrophages,
natural killer cells (NK), antigen-specific cytotoxic T-lymphocytes, and the release
of various cytokines in response to an antigen. Cellular immunity can protect the
body by activating antigen-specific T-lymphocytes. These cells induce apoptosis in
body cells displaying epitopes of foreign antigen on their surface, such as virus-
infected cells, cells infected with intracellular bacteria, and cancer cells displaying
tumor antigens. T cells activate macrophages and natural killer cells, enabling them
to destroy intracellular pathogens, and stimulating cells to secrete a variety of
cytokines that influence the function of other cells involved in adaptive and innate
immune responses. Cell-mediated immunity is directed primarily at microbes that
survive in phagocytes and microbes that infect non-phagocytic cells. It is most
effective in removing virus-infected cells, but also participates in defending against
fungi, protozoans, cancers, and intracellular bacteria.
Traditionally, as defined by the World Health Organization, a vaccine is any
preparation intended to produce immunity to a disease by stimulating the production
of antibodies. Vaccines include, for example, suspensions of killed or attenuated
microorganisms, or products or derivatives of microorganisms. The most common
method of administering vaccines is by inoculation, but some are given by mouth or
nasal spray.
Present vaccine technologies rely on large doses of antigen and/or re-
vaccinations (booster shots) and do not confer protection against all infectious
agents. Therefore, a need exists for new vaccines to confer protection against
infectious agents for which there currently are no effective vaccines. There is also a
need for new vaccines that are safer to administer, are less expensive to produce,
and/or do not require booster shots. The elimination of booster shots would increase
immunization compliance. Finally, some human populations, such as the elderly,
make overall weaker responses to vaccination, and more effective vaccines could
better protect this growing category of vaccine recipients.
SUMMARY OF THE INVENTION
In one aspect, the invention provides a compound comprising at least one
antigen directly covalently bound to an antibody-recognition epitope (ARE),
wherein the ARE is a VP-1 epitope of polio virus of about 11-28 amino acids in
length comprising IPALTAVETGA (SEQ ID NO: 1).
In another aspect, the invention provides a complex comprising the
compound of the invention operably linked to a conjugation molecule.
In another aspect, the invention provides a composition comprising the
compound of the invention or the complex of the invention and a physiologically-
acceptable, non-toxic vehicle.
In another aspect, the invention relates to the use of the compound of the
invention, or the complex of the invention, in the manufacture of a medicament for
eliciting an immune response in a pre-immunized animal.
In another aspect, the invention relates to the use of the compound of the
invention, or the complex of the invention, in the manufacture of a medicament for
generating antibodies specific for an antigen in a pre-immunized animal.
In another aspect, the invention relates to the use of the compound of the
invention, or the complex of the invention, in the manufacture of a medicament for
treating cancer.
In another aspect, the invention relates to the use of the compound of the
invention, or the complex of the invention, in the manufacture of a medicament for
preventing or treating an infection or infectious disease.
In another aspect, the invention provides a compound comprising at least one
purified antigen directly covalently bound to an antibody-recognition epitope
(ARE), wherein the ARE is the VP-1 epitope of a VP-1 epitope of polio virus of
about 11-28 amino acids in length comprising IPALTAVETGA (SEQ ID NO: 1),
for use in the prophylactic or therapeutic treatment of an infectious agent or cancer.
In another aspect, the invention provides a compound comprising at least one
purified antigen directly covalently bound to an antibody-recognition epitope
(ARE), wherein the ARE is the VP-1 epitope of a VP-1 epitope of polio virus of
about 11-28 amino acids in length comprising IPALTAVETGA (SEQ ID NO: 1),
for the manufacture of a medicament useful for the treatment of an infectious agent
or cancer in a mammal.
In another aspect, the invention provides a compound comprising at least one
antigen covalently bound to an antibody-recognition epitope (ARE), wherein the
antigen is Nucleocapsid Protein (NP) from Influenza A H5N1
(A/Indonesia/5/2005(H5N1)) Genebank protein accession number #ABI36003 and
the ARE is the VP-1 epitope of a VP-1 epitope of polio virus of about 11-28 amino
acids in length comprising IPALTAVETGA (SEQ ID NO: 1), and wherein the ARE
is covalently bound directly to the NP.
In another aspect, the invention provides a compound comprising at least one
antigen covalently bound to an antibody-recognition epitope (ARE), wherein the
antigen is Nucleocapsid Protein (NP) from Influenza A H1N1 (A/Puerto Rico/8-
V24/1934 (H1N1)) Genebank accession number ADY00024.1 and the ARE is a VP-
1 epitope of a VP-1 epitope of polio virus of about 11-28 amino acids in length
comprising IPALTAVETGA (SEQ ID NO: 1), and wherein the ARE is covalently
bound directly to the NP.
In another aspect, the invention provides a compound comprising at least one
antigen covalently bound to an antibody-recognition epitope (ARE), wherein the
antigen is Hemagglutinin Protein (HA) from Influenza A H1N1 (A/Puerto Rico/8-
V24/1934(H1N1)) Genebank accession number ADY00020.1 and the ARE is a VP-
1 epitope of a VP-1 epitope of polio virus of about 11-28 amino acids in length
comprising IPALTAVETGA (SEQ ID NO: 1), and wherein the ARE is covalently
bound directly to the HA.
In another aspect, the invention provides a compound comprising at least one
antigen covalently bound to an antibody-recognition epitope (ARE), wherein the
antigen is Hepatitis B surface antigen (HBsAg) from Hepatitis B virus and the ARE
is the VP-1 epitope of a VP-1 epitope of polio of about 11-28 amino acids in length
comprising IPALTAVETGA (SEQ ID NO: 1), and wherein the ARE is covalently
bound directly to the HBsAg.
Certain statements that appear below are broader than what appears in the
statements of the invention above. These statements are provided in the interests of
providing the reader with a better understanding of the invention and its practice.
The reader is directed to the accompanying claim set which defines the scope of the
invention.
In certain embodiments, described is a compound comprising at least one
antigen covalently bound to an antibody-recognition epitope (ARE, also called
“antibody recognition elements” or “antibody reactive epitopes”). In certain
embodiments, described is a VP-1 epitope of polio of about 11-28 amino acids in
length comprising IPALTAVETGA (SEQ ID NO: 1). In certain embodiments, the
epitope is about 18-28 amino acids in length and comprises IPALTAVETGA (SEQ
ID NO: 1). In certain embodiments, the epitope consists essentially of, or consists
of, IPALTAVETGA (SEQ ID NO: 1).
In certain embodiments the epitope is about 11-28 amino acids in length and
comprises ALTAVETGAT (SEQ ID NO: 3). In certain embodiments, described is a
VP-1 epitope of polio of about 18-28 amino acids in length comprising
ALTAVETGAT (SEQ ID NO: 3). In certain embodiments the epitope consists
essentially of, or consists of, ALTAVETGAT (SEQ ID NO: 3). In certain
embodiments the epitope is 18-28 amino acids in length and comprises, consists
essentially of, or consists of AHSKEIPALTAVETGATA (SEQ ID NO: 2).
In certain embodiments, described is a compound comprising at least one
antigen covalently bound to an antibody-recognition epitope (ARE), wherein the
ARE is a VP-1 epitope described above. In certain embodiments, the antigen is
bound to the ARE by means of an alpha-Gal linkage. In certain embodiments, the
antigen is bound to the ARE by means of linker molecule. In certain embodiments,
the linker molecule is formaldehyde, gluteraldehyde, MBS (m-Maleimidobenzoyl-
N-hydroxysuccinimide ester) and/or Sulfo-MBS. In certain embodiments, the
antigen is an infectious agent antigen. In certain embodiments, the infectious agent
is a bacterial, fungal, parasitic, viral, or prion agent. In certain embodiments, the
infectious agent is a bacterial agent or a viral agent. In certain embodiments, the
antigen is a cancer antigen.
In certain embodiments, the antigen is further conjugated to an antibody to
form an antibody:antigen complex. As used herein, the term “antibody” includes
scFv, humanized, fully human or chimeric antibodies, single-chain antibodies,
diabodies, and antigen-binding fragments of antibodies (e.g., Fab fragments). In
certain embodiments, the antibody is a human antibody or a humanized antibody. In
certain embodiments, the antibody is a single-chain Fv or an scFv fragment.
In certain embodiments, the hapten is operably linked to the antigen to form
a haptenated antigen. In certain embodiments, the hapten is operably linked to a
further antigen.
In certain embodiments, described is a complex comprising a compound
comprising at least one antigen covalently conjugated to an antibody-recognition
epitope (ARE) operably linked to a conjugation molecule. In certain embodiments,
the conjugation molecule is a peptide, a nucleic acid, or a polysaccharide that is not
the antigen or ARE.
In certain embodiments, described is a composition comprising a compound
comprising at least one antigen conjugated to an antibody-recognition epitope
(ARE) and a physiologically-acceptable, non-toxic vehicle. In certain embodiments,
the composition, further comprises an adjuvant.
In certain embodiments, described is a method of eliciting an immune
response in a pre-immunized animal comprising introducing into the animal the
composition described above. In certain embodiments, the introduction of the
composition occurs at least 15 days after the pre-immunization. In certain
embodiments, the method further comprises introducing a second composition
described above. In certain embodiments, the method further comprises introducing
a repeat dose of the composition. In certain embodiments, the animal is a human.
In certain embodiments, described is a method of generating antibodies
specific for an antigen, comprising introducing into the animal the composition or
complex described above. In certain embodiments, the method further comprises
introducing a second dose of the composition or the complex into the animal.
In certain embodiments, described is a method of treating cancer, comprising
administering to a patient the composition or the complex described above.
In certain embodiments, described is a method of preventing or treating an
infection or infectious disease comprising administering to a patient the composition
or the complex described above.
In certain embodiments, described is a compound comprising at least one
antigen conjugated to an antibody-recognition epitope (ARE) for use in the
prophylactic or therapeutic treatment of an infectious agent or cancer.
In certain embodiments, described is a compound comprising at least one
antigen conjugated to an antibody-recognition epitope (ARE) for the manufacture of
a medicament useful for the treatment of an infectious agent or cancer in a mammal.
Also described is a compound comprising at least one antigen covalently
bound to an antibody-recognition epitope (ARE), wherein the antigen is
Nucleocapsid Protein (NP) from Influenza A H5N1 (A/Indonesia/5/2005(H5N1))
Genebank protein accession number #ABI36003 and the ARE is VP-1 epitope of
polio of about 11-28 amino acids in length comprising IPALTAVETGA (SEQ ID
NO: 1), and wherein the ARE is covalently bound directly to the NP.
In certain embodiments, described is a nucleic acid encoding the VP-1
epitope described above operably linked to nucleic acid encoding an antigen.
In certain embodiments, described is an expression cassette comprising a
promoter contiguously linked to a nucleic acid encoding the VP-1 epitope described
above operably linked to nucleic acid encoding an antigen. In certain embodiments,
the promoter is a tissue-specific promoter. In certain embodiments, the promoter is
an inducible promoter. In certain embodiments, the promoter is a CMV, RSV, EFa-
1, or T7 promoter.
In certain embodiments, described is a vector comprising the expression
cassette described above. In certain embodiments, the vector is an adeno-associated
virus (AAV) vector.
BRIEF DESCRIPTION OF THE FIGURES
Fig. 1 Proposed mechanism(s) of enhanced cellular immune response to Ab-
recognition element (ARE) conjugated Ags. Mouse groups I and II have humoral
response to AgA. Group I is then immunized with AgB conjugated to AgA derived
AREs. In contrast, Group II is immunized against a non-conjugated AgB. AgA
specific humoral response recognizing ARE conjugated AgB enhance the B-specific
adaptive immune response of Group I over that of Group II.
Fig. 2 shows memory CD8 T cell responses.
Fig. 3 shows a timeline for when mice are injected with antigen and the days
on which blood is collected to test for Ag1 and hapten-specific antibodies.
Fig. 4 shows the in vitro experimental design to test the role of secreted Ig
and the in vivo experimental design for the role of soluble Ig in enhanced immune
responses.
Fig. 5 shows timelines for the ARE-conj vaccinations in succession and for
concurrent ARE-conj vaccinations.
Fig. 6 shows Immune Banking, which is the exploitation of pre-existing Ab
response to an ARE hapten, 2,4,6, Trinitrophenyl (TNP), provides protection against
influenza induced death.
Fig. 7 shows the role of soluble Ag-specific immunoglobulin in enhanced
responses. Serum from KLH or KLH-TNP immunized mice was incubated with
TNP conjugated ovalbumin. The resulting mixtures containing ovalbumin-TNP plus
mouse serum or ovalbumin-TNP:antibody complexes were injected into naïve mice
(3 per group). Seven days post ovalbumin injection the percent of ova-specific
splenic CD8 T cells was determined by intracellular cytokine staining. Note that the
injection of immune complexes using TNP as an ARE enhances the cellular
response to the vaccine.
Fig. 8 shows the determination of the efficacy of ARE modified peptide
vaccines. Mice with ARE specific antibodies show less morbidity after vaccination
and challenge with Influenza. Mice were either mock vaccinated (alum w/ PBS) or
immunized against Hepatitis B using the human vaccine (HBsAg – in alum). Upon
sero-conversion to HBsAg in the test group, both groups of mice received a
Hepatitis ARE tagged influenza nucleoprotein vaccine (HepPep- covalently linked
to the nucleoprotein -NP- of influenza). Both groups were then challenged with
virulent influenza and morbidity determined by weightloss. The HepPep-ARE
tagged vaccine group shows less morbidity than the control group.
Fig. 9 shows the results of VP-1 ARE chemically linked to the HBsAg and
given as an immune complex.
DETAILED DESCRIPTION OF THE INVENTION
The development of technologies to increase the immunogenicity of subunit
vaccines is of major interest to health professionals, military personnel, and the
general public. The ability to increase an antigen’s immunogenicity improves
current vaccines and enhances the development of new vaccines, to reduce infection
related morbidity and mortality. In addition to combating infectious diseases,
advances in vaccine development benefits cancer patients and suffers of chemical
dependence (e.g., vaccination against active chemicals such as cocaine) through
immunotherapeutics and immunologic intervention respectively.
Successful immunization results in activation of adaptive immune cells
including B lymphocytes (also called “B cells”). B cell activation induces clonal
expansion and differentiation into long lived Ab producing cells (plasma cells) and
memory B cells. Thus immunized individuals express soluble Abs and maintain
memory B cells, each able to recognize particular Ags contained within the original
vaccine.
In certain embodiments, described is a process called “Immune Banking”
that enhances vaccine efficacy by exploiting existing humoral responses. The
Immune Banking process involves tagging new antigens with molecular markers
that are already recognized by an existing antibody response in an individual. This
recognition of the tagged vaccine components enhances adaptive immune responses
to the new vaccine. Previous vaccine technologies relied on large doses of antigen
and/or re-vaccinations (booster shots) and did not confer protection against all
infectious agents. Because the Immune Banking process is able to enhance the
efficacy of vaccines, it can be used to lower dose requirements for current vaccines,
reducing cost of manufacture, and reduce need for booster shots (which would
increase immunization compliance). The Immune Banking process also enables the
creation of new vaccines to combat emerging infectious agents and cancer for which
vaccines do not yet exist. This process also enhances the production of monoclonal
and polyclonal antibodies for research uses or clinical treatments. The Immune
Banking technology is therefore of great interest to producers of vaccines for both
human and animals, biotechnology companies that produce polyclonal and
monoclonal antibodies for experimental research, and pharmaceutical companies
that produce monoclonal antibodies for treatment of disease.
In certain embodiments, the present invention expands the efficacy of
vaccine response, and thus the number of people that respond to a particular vaccine.
It also increases the effectiveness of vaccines in newborns. The use of this process
overcomes multiple problems in current uses of vaccines including the requirement
for multiple vaccinations or “booster shots,” need for large dose of vaccine
components, inability to vaccinate newborns, difficulty in producing effective
vaccines that protect against particular infectious agents, and challenges in preparing
vaccines that protect against cancer. Multiple studies have suggested that increasing
the efficacy of vaccines through targeting or directed antigens (Ag) to immune cells
would help solve these problems. Targeting of antigens to immune cells has been
accomplished in laboratory settings by conjugation of Ag with cell-specific ligands
or cell-specific antibodies, but the large scale production and development of such
vaccines is cost preventative and faces considerable technological obstacles. A
simple, effective, cost efficient way to target vaccines antigens to antigen presenting
cells (APCs) is therefore paramount. The Immune Banking process achieves this
goal by utilizing pre-existing humoral immune response to target or direct vaccine
antigens to immune cells, therefore enhancing the immune response to the vaccine.
In certain embodiments, an animal (e.g., human) is pre-immunized against a
known antigen to generate an initial immune response (i.e., a vaccine is
administered, and the animal’s immune system mounts an immune response). The
pre-immunized animal is then administered a compound comprising at least one
antigen conjugated to an antibody-recognition epitope (ARE). The Immune
Banking builds on the fact that both animals and humans are routinely subjected to
vaccinations with known antigens. In certain embodiments, the Immune Banking
vaccines are modified with haptenated antigens, and in certain situations, the
Immune Banking vaccines have additional antigens conjugated to them. In certain
embodiments, the ARE is VP-1 epitope of polio of about 11-28 amino acids in
length comprising IPALTAVETGA (SEQ ID NO: 1). In certain embodiments, the
ARE is conjugated to the antigen by means of an alpha-Gal linkage.
Improvement of vaccine immunogenicity by exploiting pre-existing
humoral responses
Increasing vaccine immunogenicity improves currently available vaccines
and enhances development of new vaccines to reduce infection related morbidity
and mortality. Vaccines targeted to antigen-presenting cells (APCs) by conjugation
of Ag with APC-specific ligands or Abs display increased immunogenicity.
However, the large scale production and development of such vaccines faces cost
and technological obstacles. A simple, effective, cost efficient way to target vaccine
Ags to APCs is lacking. Successful immunization results in B cell activation, which
induces clonal expansion and differentiation into long lived Ab producing plasma
and memory B cells. Thus, immunized individuals have soluble Abs and memory B
cells, each able to recognize Ags from the original vaccine. The present inventors
utilize AREs from one immunization to modify new Ags, thus targeting them to
APCs by exploiting existing B memory responses. Specific Ag targeting to APCs
uses an existing humoral immune response, and improves immunogenicity of a
vaccine. This results in both increased vaccine efficacy and a reduction in the need
for repeated immunizations.
Regulation of new Ab responses by pre-existing Abs, a phenomenon known
as Ab feedback regulation, was originally described in 1892 by Emil von Berhing
(Hjelm, F., et al. 2006. Scand J Immunol 64:177-184). Depending on the
experimental model, the regulation of new Ab responses can be positive
(enhancement) or negative (suppressive) (Heyman, B. 2000. Annu Rev Immunol
18:709-737). While not completely understood, the mechanisms of enhancement
are thought to be dependent upon FcR mediated uptake of Ab:Ag complexes
followed by presentation of Ag to CD4 T cells by APCs. These T cells can then
provide “help” to new Ag-specific B cells thereby enhancing Ab responses
(Heyman, B. 2000. Annu Rev Immunol 18:709-737; Getahun, A., and B. Heyman.
2006. Immunol Lett 104:38-45). Interestingly, while discussed over 100 years ago
and believed to involve T lymphocytes, the effect of Ab feedback regulation on CD4
and CD8 T cell responses has not been determined. The experiments outlined herein
evaluate the effects of pre-existing humoral responses on generating T cell responses
to new Ag, and potential usefulness as a new immunization enhancement strategy.
Fig. 1 provides the proposed mechanism(s) of enhanced cellular immune
response to ARE conjugated Ags. Mouse groups I and II have humoral responses to
AgA. Group I is immunized with AgB conjugated to Ag-A derived AREs. Group II
is immunized against a non-conjugated Ag-B. Ag-A specific humoral responses
recognizing ARE- conjugated AgB enhance the lymphocyte-specific adaptive
immune response of Group I over that of Group II.
Table 1 and Figure 2 show that pre-existing humoral responses to AREs
enhanced CD8 T cell responses to ARE-conjugated, novel immunogens.
Table 1
Role of pre-existing Ab responses in enhancing adaptive immune response to
novel Ags.
First, the kinetics of humoral immunity-enhanced T and B cell response are
measured. Durable Ag-specific Ab, a measure of vaccine efficacy, results from B
cell activation, which leads to generation of long lived Ab producers. Abs provide
immune protection in part through opsonization of Ag that facilitates its
phagocytosis by immune cells expressing FcRs. Internalized Ag is processed for
presentation to T lymphocytes. To quantify the primary response of naïve B cells to
vaccination, groups of 5 C57Bl/6 mice are injected with TNP-KLH or control Ags
(KLH, KLH-NP, BSA-TNP). On day-0 sera is harvested, followed by i.p.
immunizations of conjugated or non-haptenated Ags – KLH, KLH-NP, KLH-TNP,
BSA-TNP or PBS alone, and a booster immunization on day-14. Sera is collected
every three days starting on day-14 and tested, together with preimmune sera, for
hapten and carrier specific IgM and IgG (see “General Methods” below). If Ag-
specific Abs are not produced after the second immunization, a third Ag injection is
given on day-28, again followed by Ag specific Ab measurement in serum every
three days (see Fig. 3).
Fig. 2 indicates that T cell responses to new Ags are enhanced when
recognized by a pre-existing Ab response (Fig. 1 model). Kinetics and phenotype of
enhanced immune responses are compared to those of mice receiving control
immunizations. To compare both peak levels of an Ag-specific response and
kinetics of humoral-enhanced vs. non-enhanced responses, mice preimmunized with
KLH-TNP or control Ags receive ova-TNP i.p. Sera is collected every second day
post ova-immunization to evaluate ova-specific Abs (ELISA) and monitor serum
cytokines (cytokine multiplex). Because the level of circulating Ag-specific T cells
is relatively low after i.p. immunization, the draining tracheobronchial (TB) LN is
isolated from 3 mice/group/time and used to evaluate T lymphocyte responses. LN
cells are cultured with or without CD4 and CD8 immunodominant peptides (Table
2, see “General Methods” below) for 6 and 24 h. Cells incubated for 6h are
analyzed by flow cytometry, for lineage specific markers (CD4 and CD8) and
intracellular IFN- γ, indicative of T lymphocyte responses. Supernatants from 24h
samples are analyzed for multiple cytokines using Luminex® multiplex.
The minimal time needed between unique ARE immunizations and exposure
to novel Ag to induce humoral enhanced responses is determined. Using the above
model, immunizations with Ova-TNP begin on day-1 after TNP-specific Abs are
found in sera of KLH-TNP immunized mice. Preimmune mice are divided into
groups based on time of Ova-TNP injections, every 3d starting at day-15, until peak
anti-TNP Ab responses. By determining the minimal time between hapten-booster
and second Ag injection necessary to observe the enhanced response, optimal
vaccination strategies are developed.
Role of soluble Ag-specific immunoglobulin in enhanced responses
The contribution of the humoral response to a T cell response is not clearly
understood. An active humoral response to an Ag enhances a CTL response to a
new Ag conjugated to the original immunogen (Fig. 2). It is likely that this
enhanced T cell response is due to increased Ag uptake through Ig dependent
mechanisms: 1) Ig:Ag complex uptake via FcR on APCs (DCs and m φ) and 2) Ag
uptake by memory B cells specific for the original Ag.
To test the role of secreted Ig in vitro, hapten-specific or pre-immune serum
are incubated with the modified fluorochrome PE (phycoerythrin) or controls (TNP-
PE, PE, or DP-PE; a non-specific hapten) (Fig. 4). BMDC (bone marrow derived
DC) from WT and Fc γR-/- mice (Takai, T., et al. 1994. Cell 76:519-529) are treated
with the PE molecules. Fluorescent Ag associated with BMDCs is quantitated using
flow cytometry. Ova cross-presentation is determined by staining BMDCs for
MHC:ova-peptide expression using MHC:SIINFEKL (SEQ ID NO:3) specific Abs.
The role of soluble Ig in enhanced immune responses in vivo is determined by
injecting serum-absorbed ova i.p. into mice and monitoring lymphocyte responses.
Serum and TB-LN are isolated and tested for ova-specific Abs, cytokines, and
lineage specific markers as described above. The role of soluble Ig is determined
via immunization in Fc γR-/- mice, where Fc γRI and III are nonfunctional (Takai, T.,
et al. 1994. Cell 76:519-529), which severely impairs APC phagocytosis of hapten-
conjugated or Ab-opsonized Ag (Wernersson, S., et al. 1999. J Immunol 163:618-
622). Conversely, the membrane IgM transgenic (tg) mouse CB-17, maintains a tg
IgM H chain that cannot be secreted (Hannum, L. et al. 2000. J Exp Med 192:931-
942). As CB-17 is H-chain Ig-tg, Ab repertoire is diminished. However, expression
of H-chain mIgM with a λ L chain confers recognition of the hapten NP, resulting in
2-4% NP specific B cells (Hannum, L. et al. 2000. J Exp Med 192:931-942; Levine,
M. et al. 2000. Proc Natl Acad Sci U S A 97:2743-2748). CB-17 is used to
determine the role of Ag-specific B cells as APCs in humoral-enhanced
immunization. In each case the mutant mice and controls are given initial KLH-NP
immunizations followed by Ova-NP, and Ova-specific responses are analyzed. CB-
17 mice are not tested for serum Ig as they do not secrete Ab. Both CB-17 and
Fc γR-/- mice are commercially available.
Determination of immune effects of repeated immunization with ARE-
modified new Ags.
Continual production of ARE Abs may be deleterious due to regulatory B
cell differentiation/expansion, interaction with inhibitory Fc γRIIb, or masking
responses to new ARE conjugated Ags via immune-complex clearance. These
experiments identify potential limitations to humoral-enhanced responses to new
ARE conjugated Ags, either concurrent or in succession (Fig. 5). Mice are first
immunized against KLH-TNP (as described above) and then Ova-TNP at times
determined for maximal T cell responses. Next, BSA-TNP is the immunogen,
followed by HEL-TNP. After each new Ag, T cell responses to all received
immunogens is monitored and compared to naïve and control immunized mice at 3d
intervals. While Ag-specific T cell responses to ova is determined by intracellular
staining (ICS) using defined MHC class I and II peptides, the immunodominant
peptides for PCC and HEL for B6 mice are unknown, so enumeration of PCC and
HEL-specific T cells use Ag presenting BMDCs. Multivalent vaccines confer
protection against multiple pathogens in one dose. It is determined whether
enhanced adaptive immunity to all ARE-modified Ags is observed if multiple ARE-
conjugated Ags are given simultaneously. Upon immunization with KLH-TNP,
mice receive a multivalent vaccine containing Ova-TNP, HEL-TNP, and PCC-TNP.
Controls receive vaccines to non-conjugated Ova, HEL, and PCC. As an additional
control for ARE-independent amplification of responses, a group of KLH-TNP
immunized mice receive a multivalent vaccine containing Ova-TNP, PCC-TNP, and
non-conjugated HEL. Comparing the HEL specific immune responses from this
group with the other two groups shows if there is ARE-independent adaptive
immune enhancement when multivalent ARE-conjugated vaccines are given.
The above experiments compare the adaptive immune responses between
mice that recognize ARE-conjugated Ags and those that do not. Fig. 2 indicates that
pre-existing Ab responses enhance CD8 T cell responses to new Ag-conjugated
AREs.
Determination of the efficacy of ARE modified peptide vaccines
The ARE strategy requires either immunizing with hapten:carrier conjugates
or using epitopes recognized from prior immunizations. The Ig-immunodominant
epitopes of many childhood vaccines are known and have potential as AREs
conjugated to new Ags. The following experiment tests the protective levels of
ARE conjugated vaccines vs. non-ARE vaccines and the usefulness of relevant
human AREs vs. haptens.
Immunogenicity of ARE modified Influenza related peptides. Using the
model described above, mice are immunized with KLH, KLH-TNP, KLH-tetanus
toxoid (TT), or TT alone. Each group are then divided and immunized with TNP or
TT-conjugated influenza protein A. Relative immune responses are then measured
by influenza-specific Ab titer (ELISA), and Ag-specific T cell responses).
Vaccine-induced protection against influenza infection. ARE-modified as
compared to traditional vaccination for protection from lethal intranasal influenza
infection is examined A 1.0X LD50 of H1N1/mouse is delivered intranasally. At 2-
day intervals T cells from the TB-LN is monitored by ICS after interaction with
immunodominant peptides from Influenza NP Ag (Methods). Lung viral titer is
enumerated/g tissue (Legge, K. L., and T. J. Braciale. 2005. Immunity 23:649-659).
An enhanced adaptive immune response, measured by NP-specific T cell activity
and Abs, is expected in mice immunized with TNP or TT conjugated KLH.
Determination of effectiveness of the ARE strategy in reducing need for
repeated immunizations.
Enhanced immunity induced by ARE modification may reduce the need for
booster shots, and thus yield higher immunization compliance. This is of particular
importance in the developing world, where individuals often travel long distances
for vaccination. The following experiment compare the immune response generated
by traditional boosted immunization with that generated by a single immunization
using an ARE modified vaccine. The Hepatitis B surface Ag (HBsAg) is used as an
immunogen. Immunization with the Hep B vaccine (containing HBsAg) requires 3
injections (d0, 30, and 180). Compliance with the injection regimen is ~ 68%
(Trevisan, A., et al. 2006. Am J Infect Control 34:465-466), due in part to time
between vaccinations.
Mice are immunized with KLH-TNP as described above. Following
seroconversion, mice receive either haptenated or equal amounts of non-haptenated
HBsAg vaccine. Mice are monitored for B and T cell responses to HBsAg every 5d
post immunization. CD4 T cell responses are monitored by ICS in response to
whole-Ag pulsed BMDCs. CD8 T cell responses specifically are measured using
MHC class I specific peptides.
While information about effects of ARE modified Hep B vaccine on T cell
responses is important, Ab titers correlate with protection against Hep B infection,
so the emphasis is on Ag-specific Ab production.
Measurable Hep B specific humoral and cellular responses are expected after
a single ARE-conjugated vaccine in contrast to three immunizations necessary with
traditional Hep B immunizations. Level of adaptive immunity after 1-2 ARE-
conjugated Hep B vaccinations is compared with responses generated by each of the
three vaccinations with the traditional strategy.
Role of soluble Ag-specific immunoglobulin in enhanced responses.
Briefly, serum from KLH or KLH-TNP immunized mice was incubated with
TNP conjugated ovalbumin (Fig. 7). The resulting mixtures containing ovalbumin-
TNP plus mouse serum or ovalbumin-TNP:antibody complexes were injected into
naïve mice (3 per group). Seven days post ovalbumin injection the percent of ova-
specific splenic CD8 T cells was determined by intracellular cytokine staining. Note
that the injection of immune complexes using TNP as an ARE enhances the cellular
response to the vaccine.
Determination of the efficacy of ARE modified peptide vaccines.
Mice with ARE specific antibodies show less morbidity after vaccination and
challenge with Influenza (Fig. 8). Mice were either mock vaccinated (alum w/ PBS)
or immunized against Hepatitis B using the human vaccine (HBsAg – in alum).
Upon sero-conversion to HBsAg in the test group, both groups of mice received a
Hepatitis ARE tagged influenza nucleoprotein vaccine (HepPep- covalently linked
to the nucleoprotein -NP- of influenza). Both groups were then challenged with
virulent influenza and morbidity determined by weightloss. The HepPep-ARE
tagged vaccine group shows less morbidity than the control group.
ARE-Ag Conjugated Compounds
Described are compounds that are conjugates of AREs and antigens, which
are optionally operably linked by means of a linker moiety.
A. Antibody Recognition Element (ARE)
An ARE (antibody recognition element) is a B cell epitope of any
immunogen. To be used commercially, it is important that the ARE be recognized
by a large pool of potential recipients. Therefore, AREs derived from commonly
used recognition elements derived from prior vaccinations or naturally occurring
infections for each recipient group are best.
The AREs useful in the present invention are peptides. In one embodiment,
the ARE is the VP-1 epitope of polio of about 11-28 amino acids in length
comprising IPALTAVETGA (SEQ ID NO: 1). In another embodiment, the ARE is
a variant of this HBsAg epitope containing an N-terminal addition of RAGG (SEQ
ID NO:10) onto the amino acid sequence. In another embodiment, the ARE is a
variant of the HBsAg epitope in that it contains other amino acids that are used as
spacers or reactive groups.
B. Antigens
The antigens that are linked to the AREs include proteinaceous components
of known human and animal infectious agents, such as bacteria, fungus, parasites,
prions and viruses, or cancer antigens. Examples of antigens that can be linked to
the AREs are antigens from various infectious diseases that affect humans including
the following:
Bacterial infectious diseases
Anthrax
Bacterial meningitis
Botulism
Brucellosis
Campylobacteriosis
Cat scratch disease
Cholera
Diphtheria
Epidemic Typhus
Gonorrhea
Impetigo
Legionellosis
Leprosy (Hansen's disease)
Leptospirosis
Listeriosis
Lyme disease
Melioidosis
MRSA infection
Nocardiosis (Nocardia asteroides or Nocardia brasiliensis)
Pertussis (Whooping cough)
Plague
40 Pneumococcal pneumonia
Psittacosis
Q fever
Rocky Mountain Spotted Fever
Salmonellosis
Scarlet fever :
Shigellosis
Syphilis
Tetanus
Trachoma
Tuberculosis
Tularemia
Typhoid fever
Typhus.
Urinary tract infections : cystitis or pyelonephritis
Fungal infectious diseases
Aspergillosis : allergic bronchopulmonary aspergillosis or pulmonary
aspergilloma or invasive aspergillosis.
Blastomycosis
Candidiasis
Coccidioidomycosis
Cryptococcosis
Histoplasmosis
Tinea pedis
Parasitic infections diseases
African trypanosomiasis
Amebiasis
Ascariasis
Babesiosis
Chagas disease
Clonorchiasis
Cryptosporidiosis
Cysticercosis
Diphyllobothriasis
Dracunculiasis
Echinococcosis
Enterobiasis
Fascioliasis
Fasciolopsiasis
40 Filariasis
Free-living amebic infection (caused by Naegleria fowleri and
Acanthamoeba)
Giardiasis
Gnathostomiasis
45 Hymenolepiasis (Hymenolepis nana or Hymenolepis diminuta)
Isosporiasis
Malaria
Metagonimiasis
Myiasis
Onchocerciasis
Pediculosis
Scabies
Taeniasis
Toxocariasis
Toxoplasmosis
Trichinellosis
Trichuriasis
Trichomoniasis
Trypanosomiasis
Prion infectious diseases
Alpers syndrome
Creutzfeldt-Jakob disease
Fatal familial insomnia
Kuru
Transmissible spongiform encephalopathy
Viral infections diseases
AIDS
Chickenpox (Varicella)
Common cold (acute viral nasopharyngitis)
Cytomegalovirus infection
Colorado tick fever
Dengue fever
Ebola haemorrhagic fever
Hand, foot and mouth disease (Coxsackie A virus)
Hepatitis
Herpes simplex
Herpes zoster
Influenza (Flu)
Lassa fever
Measles
Marburg haemorrhagic fever
Infectious mononucleosis.
Mumps
Poliomyelitis
40 Progressive multifocal leukencephalopathy
Rabies
Rubella
SARS
Smallpox (Variola) : caused by Variola major and Variola minor.
45 Viral encephalitis
Viral gastroenteritis
Viral meningitis
Viral pneumonia
West Nile disease
Yellow fever
The antigens useful in the present invention may also be of veterinary origin.
See, e.g., Veterinary Microbiology 2 Edition; Hirsh, DC; MacLachlan, NJ; and
Walker, RL.; Blackwell Publishing.
In certain embodiments the Nucleocapsid Protein (NP) from Influenza A
H5N1 (A/Indonesia/5/2005(H5N1)) Genebank protein accession number
#ABI36003 is used as the antigen.
C. Couplers/Linkers
ARE-antigen coupling is done either directly or using chemical linkers in
accord with conventional practice.
In certain embodiments, the ARE and antigen molecules are covalently
linked using a chemical cross-linking agent. Many different cross-linking agents
can be used. In certain embodiments the cross-linking agent is about 400-1000
daltons or about 3-12 angstroms in length. The cross-linkers useful in the present
invention must be at least bivalent so that they can covalently join two molecules,
the ARE to the antigen molecule. In certain embodiments, the cross-linker can be
tris-succinimidyl aminotriacetate (TSAT); bis(sulfosuccinimidyl) suberate (BS3);
disuccinimidyl suberate (DSS); bis (2-[sulfosuccinimidyooxycarbonloxy]
ethylsulfone) (BOSCOES); bis(2-[succinimidyooxycarbonloxy]ethylsulfone) (Sulfo-
BOSCOES); ethylene glycol bis-(succinimidylsuccinate) (EGS); ethylene glycol
bis-(sulfosuccinimidylsuccinate) (Sulfo-EBS); or Dimethyl 3,3 ′-dithiobis-
propionimidate (DTBP). In certain embodiments, the cross-linker is bivalent such
as BS3, Sulfo-Boscoes, EGS, Sulfo-EBS, or DTBP.
Methods for attaching cross-linkers are well known in the art (c.f.
Hermanson, 1995 Bioconjugate Techniques, Academic Press, Inc. New York, pp.
728; Wong, 1991 Chemistry of Protein Conjugation and Cross-linking. CRC Press,
pp. 340; Brinkley, 1992 A brief survey of methods for preparing protein conjugates
with dyes, haptens and cross-linking reagents Bioconjugate Chem. 3:2-13).
Examples of suitable linkers include formaldehyde, gluteraldehyde, MBS
(m-Maleimidobenzoyl-N-hydroxysuccinimide ester) and/or Sulfo-MBS (the water
soluble analog of MBS), etc. Examples of couplers/linkers are described in detail on
the world-wide-web at solulink.com/white_papers/peptide and at piercenet.com and
at piercenet.com/products/browse.cfm?fldID=020306.
General methods and procedures:
Ag conjugation. KLH-TNP and ova-TNP are commercially available
(Biosearch Technologies). Additional conjugates are made by reduction using TNP-
e-Aminocaproyl-O-Su (Biosearch) in the presence of vaccine Ags. T cell activity is
monitored by ICS. Peritoneal draining TB-LN is harvested as described above. LN
is homogenized and cell number/LN enumerated. Cell suspensions are treated with
or without Ag-specific MHC class I or class II restricted peptides (Table 2) in the
presence of brefeldin A and incubated for 6h.
Table 2
Mouse Antigen MHC class I MHC class II epitope
strain epitope
CH57BI/6 ovalbumin SIINFEKL (SEQ ISQAVHAAHAEINEAGR (SEQ
ID NO. 3) ID NO. 6)
CH57BI/6 Influ - NP ASNENMETM QVYSLIRPNENPAHK (SEQ ID
(SEQ ID NO. 34) NO. 7)
CH57BI/6 Influ - NP Unknown RSALILRGSVAHKSC (SEQ ID
NO. 8)
CH57BI/6 PCC Unknown Unknown
CH57BI/6 HEL Unknown Unknown
CH57BI/6 HBsAg IPQSLDSWWTSL CTTPAQGNSMFPSCCCTKPTD
(SEQ ID NO. 5) GNC (SEQ ID NO. 9)
Samples are stained for surface expression markers of T cell subsets, fixed
and permeabilized, and stained for intracellular IFN- γ. Flow cytometry determines
the % of IFN- γ+ (Ag-responsive) CD4+ and CD8+ T cells (Kraus, Z. J., et al. 2008.
J Immunol 181:7800-7809). If MHC class I and class II immunodominant peptides
are unknown (Table 2), syngeneic BMDCs are generated and used as APCs
(Breckpot, K., et al. 2004. J Gene Med 6:1175-1188; Sudowe, S., et al. 2003. Mol
Ther 8:567-575; Bros, M., et al. 2009. J Immunol Methods 343:13-20). To stimulate
Ag specific CD4 T cells, BMDCs are pulsed with Ag for 24h allowing the cells to
process and present via MHC class II. Because CD8+ T cell Ags are more
efficiently generated from intracellular sources, the loading of MHC class I is
accomplished by transfecting BMDCs with DNA encoding the desired Ag. After
transfection the BMDCs are allowed 36h to produce, process, and present Ag.
These BMDCs, together with nonpulsed-BMDCs, are then used as APCs for
stimulation of T cells derived from the TB-LN.
Humoral response analysis is performed by measuring Ag-specific serum
Abs. Ag-specific ELISAs are as previously described (Xie, P., et al. 2007. Immunity
27:253-267; Stunz, L. et al. 2004. Immunity 21:255-266). 20 Abs to mouse IgM and
IgG are used to detect Ag-specific serum Abs. OD readings > 2 fold above
background are considered positive (Xie, P., et al. 2007. Immunity 27:253-267;
Stunz, L. et al. 2004. Immunity 21:255-266). Cytokines are measured in serum and
cell cultures using multiplex Luminex. Serum samples are collected during LN
harvest. Cells isolated from the TB-LN are stimulated with peptides as described.
Supernatants are collected after 24h and subjected to multiplex cytokine assays.
Immune Banking
Current adjuvant systems induce global, non-specific immune activity that
can result in inflammation, tissue damage, or even autoimmune disease-like
syndromes. One of the novel advantages of the Immune Banking process is the use
of pre-existing antibodies as endogenous adjuvants, able to induce a robust immune
response. In contrast to current adjuvants, however, this response is highly specific
to the immunizing antigen, and does not result in global, non-specific immune
triggering. Because the pre-existing immune response Immune Baking exploits is
created and sustained by the recipient as a natural defense against foreign
biomolecules, this technology reduces adjuvant side-effects and is better tolerated by
recipients.
In one example, Immune Banking exploited pre-existing Ab response to an
ARE hapten, TNP, and provided protection against influenza induced death. Mice
vaccinated with alum alone, KLH in alum, or KLH-TNP in alum were immunized
against influenza using a TNP-haptenated recombinant nucleocapsid protein (NP) of
influenza (Fig. 6). Mice were then infected with a lethal dose of influenza and
monitored for disease. Mice immunized with KLH-TNP showed a 66% survival
rate compared to the control groups with 0% survival.
Linking of ARE to Antigens
In certain embodiments, VP-1 ARE were chemically linked to the HBsAg
and administered as an immune complex. In other words, the HBsAg was
chemically linked to the VP-1 ARE and then mixed with an antibody that recognizes
the ARE. The complex of ARE-tagged HBsAg + Antibody was then injected as a
vaccine and compared to HBsAg without antibody. The result was a robust immune
response to the HBsAg as measured by generation of HBsAg-specific antibodies.
In certain embodiments, the ARE was linked to the antigen through
recombinant DNA technology, i.e., the construct was made as a fusion protein that
effectively functions as an ARE.
Vaccines
In certain embodiments, described are vaccines for use to protect mammals
against the colonization and/or infection of infectious agents or to treat cancer.
"Hapten" refers to a low-molecular weight organic compound that is not
capable of eliciting an immune response by itself but will elicit an immune response
once attached to a carrier molecule. Exemplary haptens used in conjugated
compounds, compositions and methods as described include drugs, hormones and
toxins, but are not limited to these specific haptens.
The term "epitope" refers to basic element or smallest unit of recognition by
an individual antibody or T-cell receptor, and thus the particular domain, region or
molecular structure to which said antibody or T-cell receptor binds. An antigen may
consist of numerous epitopes while a hapten, typically, may possess few epitopes.
As used herein "correspond essentially to" refers to an epitope that will elicit an
immunological response at least substantially equivalent to the response generated
by the native epitope. An immunological response to a composition or vaccine is
the development in the host of a cellular and/or antibody-mediated immune response
to the polypeptide or vaccine of interest. Usually, such a response consists of the
subject producing antibodies, B cell, helper T cells, suppressor T cells, and/or
cytotoxic T cells directed specifically to an antigen or antigens included in the
composition or vaccine of interest. Vaccines as described can also include effective
amounts of immunological adjuvants, known to enhance an immune response. An
"effective amount" refers to an amount necessary or sufficient to realize a desired
biologic effect. An effective amount of the composition would be the amount that
achieves this selected result, and such an amount could be determined as a matter of
routine by a person skilled in the art. For example, an effective amount for treating
an immune system deficiency could be that amount necessary to cause activation of
the immune system, resulting in the development of an antigen specific immune
response upon exposure to antigen. The term is also synonymous with "sufficient
amount." The effective amount for any particular application can vary depending on
such factors as the disease or condition being treated, the particular composition
being administered, the size of the subject, and/or the severity of the disease or
condition. One of ordinary skill in the art can empirically determine the effective
amount of a particular composition of the present invention without necessitating
undue experimentation.
The term "adjuvant" as used herein refers to non-specific stimulators of the
immune response or substances that allow generation of a depot in the host, which
when combined with the vaccine and pharmaceutical composition, respectively,
may provide for an even more enhanced immune response. A variety of adjuvants
can be used. Examples include complete and incomplete Freund's adjuvant,
aluminum hydroxide and modified muramyldipeptide. Further adjuvants are
mineral gels such as aluminum hydroxide, surface active substances such as
lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet
hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG
(bacille Calmette-Guerin) and Corynebacterium parvum. Such adjuvants are also
well known in the art. Further adjuvants that can be administered with the
compositions of the invention include, but are not limited to, Monophosphoryl lipid
immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts
(Alum), MF-59, OM-174, OM-197, OM-294, and Virosomal adjuvant technology.
The adjuvants can also comprise a mixture of these substances.
To immunize a subject, the composition is administered parenterally, usually
by intramuscular or subcutaneous injection in an appropriate vehicle. Other modes
of administration, however, such as oral, intranasal or intradermal delivery, are also
acceptable.
Vaccine formulations will contain an effective amount of the active
ingredient in a vehicle, the effective amount being readily determined by one skilled
in the art. The active ingredient may typically range from about 1% to about 95%
(w/w) of the composition, or even higher or lower if appropriate. The quantity to be
administered depends upon factors such as the age, weight and physical condition of
the animal or the human subject considered for vaccination. The quantity also
depends upon the capacity of the animal's immune system to synthesize antibodies,
and the degree of protection desired. Effective dosages can be readily established by
one of ordinary skill in the art through routine trials establishing dose response
curves. The subject is immunized by administration of the biofilm peptide or
fragment thereof in one or more doses. Multiple doses may be administered as is
required to maintain a state of immunity to the bacterium of interest.
Intranasal formulations may include vehicles that neither cause irritation to
the nasal mucosa nor significantly disturb ciliary function. Diluents such as water,
aqueous saline or other known substances can be employed with the subject
invention. The nasal formulations may also contain preservatives such as, but not
limited to, chlorobutanol and benzalkonium chloride. A surfactant may be present
to enhance absorption of the subject proteins by the nasal mucosa.
Oral liquid preparations may be in the form of, for example, aqueous or oily
suspension, solutions, emulsions, syrups or elixirs, or may be presented dry in tablet
form or a product for reconstitution with water or other suitable vehicle before use.
Such liquid preparations may contain conventional additives such as suspending
agents, emulsifying agents, non-aqueous vehicles (which may include edible oils),
or preservative.
To prepare a vaccine, the purified composition can be isolated, lyophilized
and stabilized. The composition may then be adjusted to an appropriate
concentration, optionally combined with a suitable vaccine adjuvant, and packaged
for use. Suitable adjuvants include but are not limited to surfactants, e.g.,
hexadecylamine, octadecylamine, lysolecithin, dimethyldioctadecylammonium
bromide, N,N-dioctadecyl-N'-N-bis(2-hydroxyethyl-propane di-amine),
methoxyhexadecyl-glycerol, and pluronic polyols; polanions, e.g., pyran, dextran
sulfate, poly IC, polyacrylic acid, carbopol; peptides, e.g., muramyl dipeptide,
aimethylglycine, tuftsin, oil emulsions, alum, and mixtures thereof. Other potential
adjuvants include the B peptide subunits of E. coli heat labile toxin or of the cholera
toxin. McGhee, J.R., et al., "On vaccine development," Sem. Hematol., 30:3-15
(1993). Finally, the immunogenic product may be incorporated into liposomes for
use in a vaccine formulation, or may be conjugated to proteins such as keyhole
limpet hemocyanin (KLH) or human serum albumin (HSA) or other polymers.
Definitions
"Bound" refers to binding or attachment that may be covalent, e.g., by
chemically coupling, or non-covalent, e.g., ionic interactions, hydrophobic
interactions, hydrogen bonds. Covalent bonds can be, for example, ester, ether,
phosphoester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus
bonds, and the like. The term "bound" is broader than and includes terms such as
"conjugated, " "coupled," "fused" and "attached."
The terms "protein," "peptide" and "polypeptide" are used interchangeably
herein. The description encompasses isolated or substantially purified protein
compositions. In the context of the present description, an "isolated" or "purified"
polypeptide is a polypeptide that exists apart from its native environment and is
therefore not a product of nature. A polypeptide may exist in a purified form or may
exist in a non-native environment such as, for example, a transgenic host cell. For
example, an "isolated" or "purified" protein, or biologically active portion thereof, is
substantially free of other cellular material, or culture medium when produced by
recombinant techniques, or substantially free of chemical precursors or other
chemicals when chemically synthesized. A protein that is substantially free of
cellular material includes preparations of protein or polypeptide having less than
about 30%, 20%, 10%, 5%, (by dry weight) of contaminating protein. When the
protein, or biologically active portion thereof, is recombinantly produced, preferably
culture medium represents less than about 30%, 20%, 10%, or 5% (by dry weight)
of chemical precursors or non-protein-of- interest chemicals. Fragments and
variants of the disclosed proteins or partial-length proteins encoded thereby are also
encompassed by the present description. By "fragment" or "portion" is meant a full
length or less than full length of the amino acid sequence of, a polypeptide or
protein.
"Naturally occurring" is used to describe an object that can be found in
nature as distinct from being artificially produced. For example, a protein or
nucleotide sequence present in an organism (including a virus), which can be
isolated from a source in nature and which has not been intentionally modified by
man in the laboratory, is naturally occurring.
A "variant" of a molecule is a sequence that is substantially similar to the
sequence of the native molecule.
"Wild-type" refers to the normal gene, or organism found in nature without
any known mutation.
"Operably-linked" refers to the association of molecules so that the function
of one is affected by the other.
The term "substantial identity" in the context of a peptide indicates that a
peptide comprises a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%,
77%, 78%, or 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, at
least 90%, 91%, 92%, 93%, or 94%, or 95%, 96%, 97%, 98% or 99%, sequence
identity to a reference sequence over a specified comparison window. Optimal
alignment is conducted using the homology alignment algorithm of Needleman and
Wunsch, J. Mol. Biol. 48:443 (1970). An indication that two peptide sequences are
substantially identical is that one peptide is immunologically reactive with
antibodies raised against the second peptide. Thus, a peptide is substantially
identical to a second peptide, for example, where the two peptides differ only by a
conservative substitution.
For sequence comparison, typically one sequence acts as a reference
sequence to which test sequences are compared. When using a sequence
comparison algorithm, test and reference sequences are input into a computer,
subsequence coordinates are designated if necessary, and sequence algorithm
program parameters are designated. The sequence comparison algorithm then
calculates the percent sequence identity for the test sequence(s) relative to the
reference sequence, based on the designated program parameters.
By "variant" polypeptide is intended a polypeptide derived from the native
protein by deletion (so-called truncation) or addition of one or more amino acids to
the N-terminal and/or C-terminal end of the native protein; deletion or addition of
one or more amino acids at one or more sites in the native protein; or substitution of
one or more amino acids at one or more sites in the native protein. Such variants
may results form, for example, genetic polymorphism or from human manipulation.
Methods for such manipulations are generally known in the art.
Thus, the polypeptides as described herein may be altered in various ways
including amino acid substitutions, deletions, truncations, and insertions. Methods
for such manipulations are generally known in the art. For example, amino acid
sequence variants of the polypeptides can be prepared by mutations in the DNA.
Methods for mutagenesis and nucleotide sequence alterations are well known in the
art. See, for example, Kunkel, Proc. Natl. Acad. Sci. USA, 82:488 (1985); Kunkel
et al., Meth. Enzymol., 154:367 (1987); U. S. Patent No. 4,873,192; Walker and
Gaastra, Techniques in Mol. Biol. (MacMillan Publishing Co. (1983), and the
references cited therein. Guidance as to appropriate amino acid substitutions that do
not affect biological activity of the protein of interest may be found in the model of
Dayhoff et al., Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found.
1978). Conservative substitutions, such as exchanging one amino acid with another
having similar properties, are preferred.
Thus, the polypeptides as described herein encompass naturally occurring
proteins as well as variations and modified forms thereof. Such variants will
continue to possess the desired activity. The deletions, insertions, and substitutions
of the polypeptide sequence encompassed herein are not expected to produce radical
changes in the characteristics of the polypeptide. However, when it is difficult to
predict the exact effect of the substitution, deletion, or insertion in advance of doing
so, one skilled in the art will appreciate that the effect will be evaluated by routine
screening assays.
Individual substitutions deletions or additions that alter, add or delete a
single amino acid or a small percentage of amino acids (typically less than 5%, more
typically less than 1%) in an encoded sequence are “conservatively modified
variations,” where the alterations result in the substitution of an amino acid with a
chemically similar amino acid. Conservative substitution tables providing
functionally similar amino acids are well known in the art. The following five
groups each contain amino acids that are conservative substitutions for one another:
Aliphatic: Glycine (G), Alanine (A), Valine (V), Leucine (L), Isoleucine (I);
Aromatic: Phenylalanine (F), Tyrosine (Y), Tryptophan (W); Sulfur-containing:
Methionine (M), Cysteine (C); Basic: Arginine (R), Lysine (K), Histidine (H);
Acidic: Aspartic acid (D), Glutamic acid (E), Asparagine (N), Glutamine (Q). In
addition, individual substitutions, deletions or additions which alter, add or delete a
single amino acid or a small percentage of amino acids in an encoded sequence are
also "conservatively modified variations."
As used herein, the term “therapeutic agent” refers to any agent or material
that has a beneficial effect on the mammalian recipient. Thus, “therapeutic agent”
embraces both therapeutic and prophylactic molecules having nucleic acid or protein
components.
“Treating” as used herein refers to ameliorating at least one symptom of,
curing and/or preventing the development of a given disease or condition.
"Antigen" refers to a molecule capable of being bound by an antibody. An
antigen is additionally capable of being recognized by the immune system and/or
being capable of inducing a humoral immune response and/or cellular immune
response leading to the activation of B- and/or T-lymphocytes. An antigen can have
one or more epitopes (B- and/or T-cell epitopes). Antigens as used herein may also
be mixtures of several individual antigens. "Antigenic determinant" refers to that
portion of an antigen that is specifically recognized by either B- or T-lymphocytes.
B-lymphocytes responding to antigenic determinants produce antibodies, whereas T-
lymphocytes respond to antigenic determinants by proliferation and establishment of
effector functions critical for the mediation of cellular and/or humoral immunity.
As used herein, the term "antibody" refers to molecules capable of binding
an epitope or antigenic determinant. This term includes whole antibodies and
antigen-binding fragments thereof, including single-chain antibodies. In certain
embodiments, the antibodies are human antigen binding antibody fragments and
include, but are not limited to, Fab, Fab' and F(ab') , Fd, single-chain Fvs (scFv),
single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either
a V or V domain. The antibodies can be from any animal origin including birds
(e.g. chicken) and mammals (e.g., human, murine, rabbit, goat, guinea pig, camel,
horse and the like). As used herein, "human" antibodies include antibodies having
the amino acid sequence of a human immunoglobulin and include antibodies
isolated from human immunoglobulin libraries or from animals transgenic for one or
more human immunoglobulins and that do not express endogenous
immunoglobulins, as described, for example, in U.S. Pat. No. 5,939,598.
As used herein, the term "monoclonal antibody" refers to an antibody
obtained from a group of substantially homogeneous antibodies, that is, an antibody
group wherein the antibodies constituting the group are homogeneous except for
naturally occurring mutants that exist in a small amount. Monoclonal antibodies are
highly specific and interact with a single antigenic site. Furthermore, each
monoclonal antibody targets a single antigenic determinant (epitope) on an antigen,
as compared to common polyclonal antibody preparations that typically contain
various antibodies against diverse antigenic determinants. In addition to their
specificity, monoclonal antibodies are advantageous in that they are produced from
hybridoma cultures not contaminated with other immunoglobulins.
The adjective "monoclonal" indicates a characteristic of antibodies obtained
from a substantially homogeneous group of antibodies, and does not specify
antibodies produced by a particular method. For example, a monoclonal antibody
useful in the present invention can be produced by, for example, hybridoma methods
(Kohler and Milstein, Nature 256:495, 1975) or recombination methods (U.S. Pat.
No. 4,816,567). The monoclonal antibodies useful in the present invention can be
also isolated from a phage antibody library (Clackson et al., Nature 352:624-628,
1991; Marks et al., J. Mol. Biol. 222:581-597, 1991). The monoclonal antibodies
useful in the present invention particularly comprise "chimeric" antibodies
(immunoglobulins), wherein a part of a heavy (H) chain and/or light (L) chain is
derived from a specific species or a specific antibody class or subclass, and the
remaining portion of the chain is derived from another species, or another antibody
class or subclass. Furthermore, mutant antibodies and antibody fragments thereof are
also contemplated (U.S. Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci.
USA 81:6851-6855, 1984).
As used herein, the term "mutant antibody" refers to an antibody comprising
a variant amino acid sequence in which one or more amino acid residues have been
altered. For example, the variable region of an antibody can be modified to improve
its biological properties, such as antigen binding. Such modifications can be
achieved by site-directed mutagenesis (see Kunkel, Proc. Natl. Acad. Sci. USA 82:
488 (1985)), PCR-based mutagenesis, cassette mutagenesis, and the like. Such
mutants comprise an amino acid sequence which is at least 70% identical to the
amino acid sequence of a heavy or light chain variable region of the antibody, more
preferably at least 75%, even more preferably at least 80%, still more preferably at
least 85%, yet more preferably at least 90%, and most preferably at least 95%
identical. As used herein, the term “sequence identity” is defined as the percentage
of residues identical to those in the antibody's original amino acid sequence,
determined after the sequences are aligned and gaps are appropriately introduced to
maximize the sequence identity as necessary.
Specifically, the identity of one nucleotide sequence or amino acid sequence
to another can be determined using the algorithm BLAST, by Karlin and Altschul
(Proc. Natl. Acad. Sci. USA, 90: 5873-5877, 1993). Programs such as BLASTN and
BLASTX were developed based on this algorithm (Altschul et al., J. Mol. Biol. 215:
403-410, 1990). To analyze nucleotide sequences according to BLASTN based on
BLAST, the parameters are set, for example, as score=100 and wordlength=12. On
the other hand, parameters used for the analysis of amino acid sequences by
BLASTX based on BLAST include, for example, score=50 and wordlength=3.
Default parameters for each program are used when using the BLAST and Gapped
BLAST programs. Specific techniques for such analyses are known in the art (see
the website of the National Center for Biotechnology Information (NCBI), Basic
Local Alignment Search Tool (BLAST); http://www.ncbi.nlm.nih.gov).
Polyclonal and monoclonal antibodies can be prepared by methods known to those
skilled in the art. For example, the antibodies can be prepared by the methods
described below.
An antigen prepared as described above is given to a mammal, such as a
mouse, rat, hamster, guinea pig, horse, monkey, rabbit, goat, and sheep. This
immunization can be performed by any existing method, including typically used
intravenous injections, subcutaneous injections, and intraperitoneal injections.
There are no restrictions as to the immunization intervals. Immunization may be
carried out at intervals of several days to several weeks, preferably four to 21 days.
A mouse can be immunized, for example, at a single dose of 10 to 100 μg (for
example, 20 to 40 μg) of the antigen protein, but the dose is not limited to these
values.
Before the first immunization, and three to seven days after the second and
subsequent immunizations, blood is collected from the animals, and the sera are
analyzed for antibody titer. To promote an immune response, an aggregating agent
such as alum is preferably used. In general, selected mammalian antibodies have
sufficiently high antigen binding affinity. Antibody affinity can be determined using
a saturation binding assay, an enzyme-linked immunosorbent assay (ELISA), or a
competitive assay (for example, radioimmunoassay).
Polyclonal antibodies can be screened by a conventional crosslinking
analysis, such as that described in "Antibodies, A Laboratory Manual (Cold Spring
Harbor Laboratories, Harlow and David Lane edit. (1988))." An alternative method
is, for example, epitope mapping (Champe et al., J. Biol. Chem. 270:1388-1394
(1995)). A preferred method for determining polypeptide or antibody titers
comprises quantifying antibody-binding affinity. In other embodiments, methods
for assessing one or more biological properties of an antibody are also used in
addition to or instead of the methods for determining antibody-binding affinity.
Such analytical methods are particularly useful because they demonstrate the
therapeutic effectiveness of antibodies. When an antibody exhibits an improved
property in such analysis, its binding affinity is generally, but not always, enhanced.
Hybridomas that are used to prepare monoclonal antibodies can be obtained,
for example, by the method of Milstein et al. (Kohler, G., and Milstein, C., Methods
Enzymol. 1981, 73, 3-46). Myeloma cells to be fused with antibody-producing cells
may be cell lines derived from any of the various animals, such as mice, rats, and
humans, which are generally available to those skilled in the art. The cell lines to be
used are drug-resistant, and cannot survive in a selective medium (e.g., HAT
medium) in an unfused state, but can survive in a fused state. 8-azaguanine-resistant
cell lines are generally used, which are deficient in hypoxanthine-guanine-
phosphoribosyl transferase and cannot grow in a hypoxanthine-aminopterin-
thymidine (HAT) medium. Myeloma cells include a variety of known cell lines, for
example, P3x63Ag8.653 (J. Immunol. (1979) 123: 1548-1550), P3x63Ag8U.1
(Current Topics in Microbiology and Immunology (1978) 81: 1-7), NS-1 (Kohler,
G. and Milstein, C., Eur. J. Immunol. (1976) 6: 511-519), MPC-11 (Margulies, D.
H. et al., Cell (1976) 8: 405-415), SP2/0 (Shulman, M. et al., Nature (1978) 276:
269-270), F0 (de St. Groth, S. F. et al., J. Immunol. Methods (1980) 35: 1-21), S194
(Trowbridge, I. S., J. Exp. Med. (1978) 148: 313-323), R210 (Galfre, G. et al.,
Nature (1979) 277: 131-133), and P3U1 (J. Exp. Med. 1979, 150:580; Curr Top
Microbiol. Immunol. 1978, 81:1). Human myeloma and mouse-human
heteromycloma cell lines can also be used to produce human monoclonal antibodies
(Kozbar, J. Immunol. 133:3001 (1984); Brodeur et al., Monoclonal Antibody
Production Techniques and Application, pp. 51-63 (Marcel Dekker, Inc., New York,
1987)). Antibody-producing cells are collected, for example, from animals
sacrificed two to three days after the final immunization. Antibody-producing cells
include spleen cells, lymph node cells, and peripheral blood cells. Spleen cells are
generally used. Specifically, tissues such as spleens or lymph nodes are excised or
collected from the various animals described above. Then, the tissues are crushed
and the resulting material is suspended in a medium or buffer, such as PBS, DMEM,
or RPMI1640, followed by filtration with a stainless mesh or the like. This is then
centrifuged to obtain antibody-producing cells of interest.
The above-described myeloma cells and antibody-producing cells are then
fused. Cell fusion is achieved by contacting the myeloma cells with the antibody-
producing cells at a ratio of 1:1 to 1:20 in a medium for animal cell culture, such as
MEM, DMEM, and RPMI-1640, at 30 to 37°C for one to 15 minutes in the presence
of a fusion-promoting agent. To promote cell fusion, the antibody-producing cells
and the myeloma cells may be fused using a commercially available cell-fusion
device, using a fusion-promoting agent, such as polyethylene glycol (mean
molecular weight 1,000 to 6,000 (Da)) or polyvinyl alcohol, or a virus for fusion,
such as Sendai virus.
Hybridomas of interest are selected from the cells after cell fusion. The
selection methods include methods using selective propagation of cells in a selective
medium. Specifically, a cell suspension is diluted with an appropriate medium, and
then the cells are plated on to microtiter plates. An aliquot of selection medium (for
example, HAT medium) is added to each well, and then the cells are cultured while
the selection medium is appropriately exchanged. The cells grown as a result can be
saved as hybridomas.
In another embodiment, antibodies or antibody fragments can be isolated
from an antibody phage library, produced by using the technique reported by
McCafferty et al. (Nature 348:552-554 (1990)). Clackson et al. (Nature 352:624-
628 (1991)) and Marks et al. (J. Mol. Biol. 222:581-597 (1991)) reported on the
respective isolation of mouse and human antibodies from phage libraries. There are
also reports that describe the production of high affinity (nM range) human
antibodies based on chain shuffling (Marks et al., Bio/Technology 10:779-783
(1992)), and combinatorial infection and in vivo recombination, which are methods
for constructing large-scale phage libraries (Waterhouse et al., Nucleic Acids Res.
21:2265-2266 (1993)). These technologies can also be used to isolate monoclonal
antibodies, instead of using conventional hybridoma technology for monoclonal
antibody production.
Methods for preparing monoclonal antibodies from the obtained hybridomas
include standard cell culture methods and methods comprising ascites production.
In cell culture methods, hybridomas are cultured for two to 14 days under standard
culture conditions (for example, at 37°C at 5% CO atmosphere), in a culture
medium for animal cells, such as RPMI-1640 or MEM containing 10 to 20% fetal
calf serum, or serum-free medium, and antibodies are then prepared from the culture
supernatant. In the method comprising ascites production, hybridomas are
administered to the peritoneal cavities of mammalian individuals of the same species
as that from which the myeloma cells are derived, and the hybridomas proliferate in
to large quantities. Ascites or serum is then collected after one to four weeks. To
enhance ascites production, for example, pristane (2,6,10,14-
tetramethylpentadecane) may be pre-administered to the peritoneal cavity.
Antibodies useful in the present invention can be purified by a method appropriately
selected from known methods, such as the protein A-Sepharose method,
hydroxyapatite chromatography, salting-out method with sulfate, ion exchange
chromatography, and affinity chromatography, or by the combined use of the same.
The present invention may use recombinant antibodies, produced by gene
engineering. The genes encoding the antibodies obtained by a method described
above are isolated from the hybridomas. The genes are inserted into an appropriate
vector, and then introduced into a host (see, e.g., Carl, A. K. Borrebaeck, James, W.
Larrick, Therapeutic Monoclonal Antibodies, Published in the United Kingdom by
Macmillan Publishers Ltd, 1990). Also described are the nucleic acids encoding the
antibodies described herein, and vectors comprising these nucleic acids.
Specifically, using a reverse transcriptase, cDNAs encoding the variable regions (V
regions) of the antibodies are synthesized from the mRNAs of hybridomas. After
obtaining the DNAs encoding the variable regions of antibodies of interest, they are
ligated with DNAs encoding desired constant regions (C regions) of the antibodies,
and the resulting DNA constructs are inserted into expression vectors.
Alternatively, the DNAs encoding the variable regions of the antibodies may be
inserted into expression vectors comprising the DNAs of the antibody C regions.
These are inserted into expression vectors so that the genes are expressed under the
regulation of an expression regulatory region, for example, an enhancer and
promoter. Then, host cells are transformed with the expression vectors to express
the antibodies. Also described are cells expressing antibodies as described. The
cells expressing antibodies include cells and hybridomas transformed with a gene of
such an antibody.
In the present invention, recombinant antibodies artificially modified to
reduce heterologous antigenicity against humans can be used. Examples include
chimeric antibodies and humanized antibodies. These modified antibodies can be
produced using known methods. A chimeric antibody includes an antibody
comprising variable and constant regions of species that are different to each other,
for example, an antibody comprising the antibody heavy chain and light chain
variable regions of a nonhuman mammal such as a mouse, and the antibody heavy
chain and light chain constant regions of a human. Such an antibody can be
obtained by (1) ligating a DNA encoding a variable region of a mouse antibody to a
DNA encoding a constant region of a human antibody; (2) incorporating this into an
expression vector; and (3) introducing the vector into a host for production of the
antibody.
A humanized antibody, which is also called a reshaped human antibody, is
obtained by substituting an H or L chain complementarity determining region
(CDR) of an antibody of a nonhuman mammal such as a mouse, with the CDR of a
human antibody. Conventional genetic recombination techniques for the preparation
of such antibodies are known (see, for example, Jones et al., Nature 321: 522-525
(1986); Reichmann et al., Nature 332: 323-329 (1988); Presta Curr. Op. Struct. Biol.
2: 593-596 (1992)). Specifically, a DNA sequence designed to ligate a CDR of a
mouse antibody with the framework regions (FRs) of a human antibody is
synthesized by PCR, using several oligonucleotides constructed to comprise
overlapping portions at their ends. A humanized antibody can be obtained by (1)
ligating the resulting DNA to a DNA that encodes a human antibody constant
region; (2) incorporating this into an expression vector; and (3) transfecting the
vector into a host to produce the antibody (see, European Patent Application No. EP
239,400, and International Patent Application No. WO 96/02576). Human antibody
FRs that are ligated via the CDR are selected where the CDR forms a favorable
antigen-binding site. The humanized antibody may comprise additional amino acid
residue(s) that are not included in the CDRs introduced into the recipient antibody,
nor in the framework sequences. Such amino acid residues are usually introduced to
more accurately optimize the antibody's ability to recognize and bind to an antigen.
For example, as necessary, amino acids in the framework region of an antibody
variable region may be substituted such that the CDR of a reshaped human antibody
forms an appropriate antigen-binding site (Sato, K. et al., Cancer Res. (1993) 53,
851-856).
Methods for obtaining human antibodies are also known. For example,
desired human antibodies with antigen-binding activity can be obtained by (1)
sensitizing human lymphocytes with antigens of interest or cells expressing antigens
of interest in vitro; and (2) fusing the sensitized lymphocytes with human myeloma
cells such as U266 (see Examined Published Japanese Patent Application No. (JP-B)
Hei 1-59878). Alternatively, the desired human antibody can also be obtained by
using an antigen to immunize a transgenic (Tg) animal that comprises a partial or
entire repertoire of human antibody genes (see Nature Genetics 7:13-21 (1994);
Nature Genetics 15:146-156 (1997); Nature 368:856-859 (1994); International
Patent Application WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585,
WO 96/34096, and WO 96/33735). Specifically, such Tg animals are created as
follows: a nonhuman mammal in which the loci of heavy and light chains of an
endogenous immunoglobulin have been disrupted, and instead, the loci of heavy and
light chains of a human immunoglobulin have been introduced via Yeast artificial
chromosome (YAC) vectors and the like, is obtained by creating knockout animals
or Tg animals, or mating such animals. The immunoglobulin heavy chain loci can
be functionally inactivated, for example, by introducing a defect at a certain site in a
J region or C region (e.g., C μ region). The immunoglobulin light chains (e.g., κ
chain) can be functionally inactivated, for example, by introducing a defect at a
certain site in a J region or C region, or a region comprising the J and C regions.
Such a humanized antibody can also be obtained from culture supernatant,
by using genetic engineering technology to transform eukaryotic cells with cDNAs
that encode each of the heavy and light chains of the antibody, or preferably vectors
comprising these cDNAs, and then culturing the transformed cells that produce the
recombinant human monoclonal antibody. The hosts are, for example, desired
eukaryotic cells, preferably mammalian cells, such as CHO cells, lymphocytes, and
myelomas.
Furthermore, techniques to obtain human antibodies by panning with a
human antibody library are known. For example, the variable region of a human
antibody is expressed as a single chain antibody (scFv) on the surface of a phage,
using phage display method, and phages that bind to the antigen can be selected. By
analyzing the genes of selected phages, the DNA sequences encoding the variable
regions of human antibodies that bind to the antigen can be determined. If the DNA
sequences of scFvs that bind to the antigen are identified, appropriate expression
vectors comprising these sequences can be constructed, and then introduced into
appropriate hosts and expressed to obtain human antibodies. Such methods are
already well known (see WO 92/01047, WO 92/20791, WO 93/06213, WO
93/11236, WO 93/19172, WO 95/01438, and WO 95/15388).
When the antibody genes have been isolated and introduced into an
appropriate host, hosts and expression vectors can be used in appropriate
combination to produce the antibodies. As eukaryotic host cells, animal cells, plant
cells, and fungal cells may be used. The animal cells include: (1) mammalian cells
such as CHO, COS, myeloma, baby hamster kidney (BHK), HeLa, and Vero cells;
(2) amphibian cells such as Xenopus oocytes; or (3) insect cells such as sf9, sf21,
and Tn5, or silkworms. Known plant cells include cells derived from the Nicotiana
genus such as Nicotiana tabacum, which can be callus cultured. Known fungal cells
include yeasts such as the Saccharomyces genus, for example Saccharomyces
cerevisiae, and filamentous fungi such as the Aspergillus genus, for example
Aspergillus niger. Prokaryotic cells can also be used in production systems that
utilize bacterial cells. Known bacterial cells include E. coli and Bacillus subtilis.
The antibodies can be obtained by transferring the antibody genes of interest into
these cells using transformation, and then culturing the transformed cells in vitro.
The isotypes of the antibodies described herein are not limited. The isotypes
include, for example, IgG (IgG1, IgG2, IgG3, and IgG4), IgM, IgA (IgA1 and
IgA2), IgD, and IgE. The antibodies useful in the present invention may also be
antibody fragments comprising a portion responsible for antigen binding, or a
modified fragment thereof. The term "antibody fragment" refers to a portion of a
full-length antibody, and generally to a fragment comprising an antigen-binding
domain or a variable region. Such antibody fragments include, for example, Fab,
F(ab') , Fv, single-chain Fv (scFv) which comprises a heavy chain Fv and a light
chain Fv coupled together with an appropriate linker, diabody (diabodies), linear
antibodies, and multispecific antibodies prepared from antibody fragments.
Previously, antibody fragments were produced by digesting natural antibodies with a
protease; currently, methods for expressing them as recombinant antibodies using
genetic engineering techniques are also known (see Morimoto et al., Journal of
Biochemical and Biophysical Methods 24:107-117 (1992); Brennan et al., Science
229:81 (1985); Co, M. S. et al., J. Immunol., 1994, 152, 2968-2976; Better, M. &
Horwitz, A. H., Methods in Enzymology, 1989, 178, 476-496, Academic Press, Inc.;
Plueckthun, A. & Skerra, A., Methods in Enzymology, 1989, 178, 476-496,
Academic Press, Inc.; Lamoyi, E., Methods in Enzymology, 1989, 121, 663-669;
Bird, R. E. et al., TIBTECH, 1991, 9, 132-137).
An "Fv" fragment is the smallest antibody fragment, and contains a complete
antigen recognition site and a binding site. This region is a dimer (V -V dimer)
wherein the variable regions of each of the heavy chain and light chain are strongly
connected by a noncovalent bond. The three CDRs of each of the variable regions
interact with each other to form an antigen-binding site on the surface of the V -V
dimer. In other words, a total of six CDRs from the heavy and light chains function
together as an antibody's antigen-binding site. However, a variable region (or a half
Fv, which contains only three antigen-specific CDRS) alone is also known to be able
to recognize and bind to an antigen, although its affinity is lower than the affinity of
the entire binding site. Thus, a preferred antibody fragment useful in the present
invention is an Fv fragment, but is not limited thereto. Such an antibody fragment
may be a polypeptide which comprises an antibody fragment of heavy or light chain
CDRs which are conserved, and which can recognize and bind its antigen.
A Fab fragment (also referred to as F(ab)) also contains a light chain
constant region and heavy chain constant region (CH1). For example, papain
digestion of an antibody produces the two kinds of fragments: an antigen-binding
fragment, called a Fab fragment, containing the variable regions of a heavy chain
and light chain, which serve as a single antigen-binding domain; and the remaining
portion, which is called an "Fc" because it is readily crystallized. A Fab' fragment is
different from a Fab fragment in that a Fab' fragment also has several residues
derived from the carboxyl terminus of a heavy chain CH1 region, which contains
one or more cysteine residues from the hinge region of an antibody. A Fab'
fragment is, however, structurally equivalent to Fab in that both are antigen-binding
fragments which comprise the variable regions of a heavy chain and light chain,
which serve as a single antigen-binding domain. Herein, an antigen-binding
fragment comprising the variable regions of a heavy chain and light chain which
serve as a single antigen-binding domain, and which is equivalent to that obtained
by papain digestion, is referred to as a "Fab-like antibody," even when it is not
identical to an antibody fragment produced by protease digestion. Fab'-SH is Fab'
with one or more cysteine residues having free thiol groups in its constant region. A
F(ab') fragment is produced by cleaving the disulfide bond between the cysteine
residues in the hinge region of F(ab') . Other chemically crosslinked antibody
fragments are also known to those skilled in the art. Pepsin digestion of an antibody
yields two fragments; one is a F(ab') fragment which comprises two antigen-
binding domains and can cross-react with antigens, and the other is the remaining
fragment (referred to as pFc'). Herein, an antibody fragment equivalent to that
obtained by pepsin digestion is referred to as a "F(ab') -like antibody" when it
comprises two antigen-binding domains and can cross-react with antigens. Such
antibody fragments can also be produced, for example, by genetic engineering.
Such antibody fragments can also be isolated, for example, from the antibody phage
library described above. Alternatively, F(ab') -SH fragments can be recovered
directly from hosts, such as E. coli, and then allowed to form F(ab') fragments by
chemical crosslinking (Carter et al., Bio/Technology 10:163-167 (1992)). In an
alternative method, F(ab') fragments can be isolated directly from a culture of
recombinant hosts.
The term "diabody (Db)" refers to a bivalent antibody fragment constructed
by gene fusion (for example, P. Holliger et al., Proc. Natl. Acad. Sci. USA 90: 6444-
6448 (1993), EP 404,097, WO 93/11161). In general, a diabody is a dimer of two
polypeptide chains. In the each of the polypeptide chains, a light chain variable
region (V ) and a heavy chain variable region (V ) in an identical chain are
connected via a short linker, for example, a linker of about five residues, so that they
cannot bind together. Because the linker between the two is too short, the V and
V in the same polypeptide chain cannot form a single chain V region fragment, but
instead form a dimer. Thus, a diabody has two antigen-binding domains. When the
V and V regions against the two types of antigens (a and b) are combined to form
V -V and V -V via a linker of about five residues, and then co-expressed, they
La Hb Lb Ha
are secreted as bispecific Dbs. The antibodies useful in the present invention may
be such Dbs.
A single-chain antibody (also referred to as "scFv") can be prepared by
linking a heavy chain V region and a light chain V region of an antibody (for a
review of scFv see Pluckthun "The Pharmacology of Monoclonal Antibodies" Vol.
113, eds. Rosenburg and Moore, Springer Verlag, N.Y., pp. 269-315 (1994)).
Methods for preparing single-chain antibodies are known in the art (see, for
example, U.S. Pat. Nos. 4,946,778; 5,260,203; 5,091,513; and 5,455,030). In such
scFvs, the heavy chain V region and the light chain V region are linked together via
a linker, preferably, a polypeptide linker (Huston, J. S. et al., Proc. Natl. Acad. Sci.
U.S.A, 1988, 85, 5879-5883). The heavy chain V region and the light chain V
region in a scFv may be derived from the same antibody, or from different
antibodies. The peptide linker used to ligate the V regions may be any single-chain
peptide consisting of 12 to 19 residues. A DNA encoding a scFv can be amplified
by PCR using, as a template, either the entire DNA, or a partial DNA encoding a
desired amino acid sequence, selected from a DNA encoding the heavy chain or the
V region of the heavy chain of the above antibody, and a DNA encoding the light
chain or the V region of the light chain of the above antibody; and using a primer
pair that defines the two ends. Further amplification can be subsequently conducted
using a combination of the DNA encoding the peptide linker portion, and the primer
pair that defines both ends of the DNA to be ligated to the heavy and light chain
respectively. After constructing DNAs encoding scFvs, conventional methods can
be used to obtain expression vectors comprising these DNAs, and hosts transformed
by these expression vectors. Furthermore, scFvs can be obtained according to
conventional methods using the resulting hosts. These antibody fragments can be
produced in hosts by obtaining genes that encode the antibody fragments and
expressing these as outlined above. Antibodies bound to various types of molecules,
such as polyethylene glycols (PEGs), may be used as modified antibodies. Methods
for modifying antibodies are already established in the art. The term "antibody" as
used herein also encompasses the above-described antibodies.
The antibodies obtained can be purified to homogeneity. The antibodies can
be isolated and purified by a method routinely used to isolate and purify proteins.
The antibodies can be isolated and purified by the combined use of one or more
methods appropriately selected from column chromatography, filtration,
ultrafiltration, salting out, dialysis, preparative polyacrylamide gel electrophoresis,
and isoelectro-focusing, for example (Strategies for Protein Purification and
Characterization: A Laboratory Course Manual, Daniel R. Marshak et al. eds., Cold
Spring Harbor Laboratory Press (1996); Antibodies: A Laboratory Manual. Ed
Harlow and David Lane, Cold Spring Harbor Laboratory, 1988). Such methods are
not limited to those listed above. Chromatographic methods include affinity
chromatography, ion exchange chromatography, hydrophobic chromatography, gel
filtration, reverse-phase chromatography, and adsorption chromatography. These
chromatographic methods can be practiced using liquid phase chromatography, such
as HPLC and FPLC. Columns to be used in affinity chromatography include protein
A columns and protein G columns. For example, protein A columns include Hyper
D, POROS, and Sepharose F. F. (Pharmacia). Antibodies can also be purified by
utilizing antigen binding, using carriers on which antigens have been immobilized.
The antibodies useful in the present invention can be formulated according to
standard methods (see, for example, Remington's Pharmaceutical Science, latest
edition, Mark Publishing Company, Easton, U.S.A), and may comprise
pharmaceutically acceptable carriers and/or additives. Also described are
compositions (including reagents and pharmaceuticals) comprising the antibodies as
described herein, and pharmaceutically acceptable carriers and/or additives.
Exemplary carriers include surfactants (for example, PEG and Tween), excipients,
antioxidants (for example, ascorbic acid), coloring agents, flavoring agents,
preservatives, stabilizers, buffering agents (for example, phosphoric acid, citric acid,
and other organic acids), chelating agents (for example, EDTA), suspending agents,
isotonizing agents, binders, disintegrators, lubricants, fluidity promoters, and
corrigents. However, the carriers that may be employed in the present invention are
not limited to this list. In fact, other commonly used carriers can be appropriately
employed: light anhydrous silicic acid, lactose, crystalline cellulose, mannitol,
starch, carmelose calcium, carmelose sodium, hydroxypropylcellulose,
hydroxypropylmethyl cellulose, polyvinylacetaldiethylaminoacetate,
polyvinylpyrrolidone, gelatin, medium chain fatty acid triglyceride, polyoxyethylene
hydrogenated castor oil 60, sucrose, carboxymethylcellulose, corn starch, inorganic
salt, and so on. The composition may also comprise other low-molecular-weight
polypeptides, proteins such as serum albumin, gelatin, and immunoglobulin, and
amino acids such as glycine, glutamine, asparagine, arginine, and lysine. When the
composition is prepared as an aqueous solution for injection, it can comprise an
isotonic solution comprising, for example, physiological saline, dextrose, and other
adjuvants, including, for example, D-sorbitol, D-mannose, D-mannitol, and sodium
chloride, which can also contain an appropriate solubilizing agent, for example,
alcohol (for example, ethanol), polyalcohol (for example, propylene glycol and
PEG), and non-ionic detergent (polysorbate 80 and HCO-50).
If necessary, antibodies as described herein may be encapsulated in
microcapsules (microcapsules made of hydroxycellulose, gelatin,
polymethylmethacrylate, and the like), and made into components of colloidal drug
delivery systems (liposomes, albumin microspheres, microemulsions, nano-particles,
and nano-capsules) (for example, see "Remington's Pharmaceutical Science 16th
edition", Oslo Ed. (1980)). Moreover, methods for making sustained-release drugs
are known, and these can be applied for the antibodies described (Langer et al., J.
Biomed. Mater. Res. 15: 167-277 (1981); Langer, Chem. Tech. 12: 98-105 (1982);
U.S. Pat. No. 3,773,919; EP Patent Application No. 58,481; Sidman et al.,
Biopolymers 22: 547-556 (1983); EP: 133,988).
An "immune response" refers to a humoral immune response and/or cellular
immune response leading to the activation or proliferation of B- and/or T-
lymphocytes and/or and antigen presenting cells. In some instances, however, the
immune responses may be of low intensity and become detectable only when using
at least one substance in accordance with the invention. "Immunogenic" refers to an
agent used to stimulate the immune system of a living organism, so that one or more
functions of the immune system are increased and directed towards the
immunogenic agent. An "immunogenic polypeptide" is a polypeptide that elicits a
cellular and/or humoral immune response, whether alone or linked to a carrier in the
presence or absence of an adjuvant. Preferably, antigen presenting cell may be
activated.
A substance that "enhances" an immune response refers to a substance in
which an immune response is observed that is greater or intensified or deviated in
any way with the addition of the substance when compared to the same immune
response measured without the addition of the substance. For example, the lytic
activity of cytotoxic T cells can be measured, e.g. using a Cr release assay, in
samples obtained with and without the use of the substance during immunization.
The amount of the substance at which the CTL lytic activity is enhanced as
compared to the CTL lytic activity without the substance is said to be an amount
sufficient to enhance the immune response of the animal to the antigen. In certain
embodiments, the immune response in enhanced by a factor of at least about 2, such
as by a factor of about 3 or more. The amount or type of cytokines secreted may also
be altered. Alternatively, the amount of antibodies induced or their subclasses may
be altered.
The terms "immunize" or "immunization" or related terms refer to conferring
the ability to mount a substantial immune response (comprising antibodies and/or
cellular immunity such as effector CTL) against a target antigen or epitope. These
terms do not require that complete immunity be created, but rather that an immune
response be produced which is substantially greater than baseline. For example, a
mammal may be considered to be immunized against a target antigen if the cellular
and/or humoral immune response to the target antigen occurs following the
application of methods as described herein.
The term "immunotherapeutic" refers to a composition for the treatment of
diseases, disorders or conditions. More specifically, the term is used to refer to a
method of treatment wherein a beneficial immune response is generated by
vaccination or by transfer of immune molecules. An "immunologically effective
amount" refers to an amount of a composition sufficient to induce an immune
response in an individual when introduced into that individual. In the context of
active immunization, the term is synonymous with "immunogenically effective
amount." The amount of a composition necessary to be immunologically effective
varies according many factors including to the composition, the presence of other
components in the composition (e.g. adjuvants), the antigen, the route of
immunization, the individual, the prior immune or physiologic state etc.
Nucleic Acid Molecules, Expression Cassettes and Expression Vectors
The AREs and conjugated compounds can be encoded by a nucleic acid
sequence, and the nucleic acid sequence can also include a promoter. The nucleic
acid sequence can also include a polyadenylation signal. In some embodiments, the
polyadenylation signal is a synthetic minimal polyadenylation signal or a sequence
of six Ts.
The term "nucleic acid" refers to deoxyribonucleic acid (DNA) or
ribonucleic acid (RNA) and polymers thereof in either single- or double-stranded
form, composed of monomers (nucleotides) containing a sugar, phosphate and a
base that is either a purine or pyrimidine. Unless specifically limited, the term
encompasses nucleic acids containing known analogs of natural nucleotides that
have similar binding properties as the reference nucleic acid and are metabolized in
a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a
particular nucleic acid sequence also encompasses conservatively modified variants
thereof (e.g., degenerate codon substitutions) and complementary sequences, as well
as the sequence explicitly indicated. Specifically, degenerate codon substitutions
may be achieved by generating sequences in which the third position of one or more
selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues.
A “nucleic acid fragment” is a portion of a given nucleic acid molecule.
A “nucleotide sequence” is a polymer of DNA or RNA that can be single-
stranded or double-stranded, optionally containing synthetic, non-natural or altered
nucleotide bases capable of incorporation into DNA or RNA polymers.
The terms “nucleic acid,” “nucleic acid molecule,” “nucleic acid fragment,”
“nucleic acid sequence or segment,” or “polynucleotide” are used interchangeably
and may also be used interchangeably with gene, cDNA, DNA and RNA encoded
by a gene.
Also described are isolated or substantially purified nucleic acid nucleic acid
molecules and compositions containing those molecules. In the context of the
present description, an “isolated” or “purified” DNA molecule or RNA molecule is a
DNA molecule or RNA molecule that exists apart from its native environment and is
therefore not a product of nature. An isolated DNA molecule or RNA molecule may
exist in a purified form or may exist in a non-native environment such as, for
example, a transgenic host cell. For example, an “isolated” or “purified” nucleic
acid molecule or biologically active portion thereof, is substantially free of other
cellular material, or culture medium when produced by recombinant techniques, or
substantially free of chemical precursors or other chemicals when chemically
synthesized. In one embodiment, an “isolated” nucleic acid is free of sequences that
naturally flank the nucleic acid (i.e., sequences located at the 5 ′ and 3 ′ ends of the
nucleic acid) in the genomic DNA of the organism from which the nucleic acid is
derived. For example, in various embodiments, the isolated nucleic acid molecule
can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of
nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA
of the cell from which the nucleic acid is derived. Fragments and variants of the
disclosed nucleotide sequences are also encompassed by the present description. By
“fragment” or “portion” is meant a full length or less than full length of the
nucleotide sequence.
“Naturally occurring,” “native,” or “wild-type” is used to describe an object
that can be found in nature as distinct from being artificially produced. For
example, a protein or nucleotide sequence present in an organism (including a
virus), which can be isolated from a source in nature and that has not been
intentionally modified by a person in the laboratory, is naturally occurring.
A “variant” of a molecule is a sequence that is substantially similar to the
sequence of the native molecule. For nucleotide sequences, variants include those
sequences that, because of the degeneracy of the genetic code, encode the identical
amino acid sequence of the native protein. Naturally occurring allelic variants such
as these can be identified with the use of molecular biology techniques, as, for
example, with polymerase chain reaction (PCR) and hybridization techniques.
Variant nucleotide sequences also include synthetically derived nucleotide
sequences, such as those generated, for example, by using site-directed mutagenesis,
which encode the native protein, as well as those that encode a polypeptide having
amino acid substitutions. Generally, nucleotide sequence variants as described will
have at least 40%, 50%, 60%, to 70%, e.g., 71%, 72%, 73%, 74%, 75%, 76%, 77%,
78%, to 79%, generally at least 80%, e.g., 81%-84%, at least 85%, e.g., 86%, 87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, to 98%, sequence identity
to the native (endogenous) nucleotide sequence.
A "transgene" refers to a gene that has been introduced into the genome by
transformation. Transgenes include, for example, DNA that is either heterologous
or homologous to the DNA of a particular cell to be transformed. Additionally,
transgenes may include native genes inserted into a non-native organism, or
chimeric genes.
The term "endogenous gene" refers to a native gene in its natural location in
the genome of an organism.
The terms "protein," "peptide" and "polypeptide" are used interchangeably
herein.
"Wild-type" refers to the normal gene or organism found in nature.
“Genome” refers to the complete genetic material of an organism.
A “vector" is defined to include, inter alia, any viral vector, as well as any
plasmid, cosmid, phage or binary vector in double or single stranded linear or
circular form that may or may not be self transmissible or mobilizable, and that can
transform prokaryotic or eukaryotic host either by integration into the cellular
genome or exist extrachromosomally (e.g., autonomous replicating plasmid with an
origin of replication).
“Expression cassette” as used herein means a nucleic acid sequence capable
of directing expression of a particular nucleotide sequence in an appropriate host
cell, which may include a promoter operably linked to the nucleotide sequence of
interest that may be operably linked to termination signals. The coding region
usually codes for a functional RNA of interest, for example an RNA encoding an
epitope or conjugated compound. The expression cassette including the nucleotide
sequence of interest may be chimeric. The expression cassette may also be one that
is naturally occurring but has been obtained in a recombinant form useful for
heterologous expression. The expression of the nucleotide sequence in the
expression cassette may be under the control of a constitutive promoter or of a
regulatable promoter that initiates transcription only when the host cell is exposed to
some particular stimulus. In the case of a multicellular organism, the promoter can
also be specific to a particular tissue or organ or stage of development.
Such expression cassettes can include a transcriptional initiation region
linked to a nucleotide sequence of interest. Such an expression cassette is provided
with a plurality of restriction sites for insertion of the gene of interest to be under the
transcriptional regulation of the regulatory regions.
“Regulatory sequences” are nucleotide sequences located upstream (5 ′ non-
coding sequences), within, or downstream (3 ′ non-coding sequences) of a coding
sequence, and which influence the transcription, RNA processing or stability, or
translation of the associated coding sequence. Regulatory sequences include
enhancers, promoters, translation leader sequences, introns, and polyadenylation
signal sequences. They include natural and synthetic sequences as well as
sequences that may be a combination of synthetic and natural sequences. As is
noted herein, the term “suitable regulatory sequences” is not limited to promoters.
However, some suitable regulatory sequences will include, but are not limited to
constitutive promoters, tissue-specific promoters, development-specific promoters,
regulatable promoters and viral promoters.
“Promoter” refers to a nucleotide sequence, usually upstream (5 ′) to its
coding sequence, which directs and/or controls the expression of the coding
sequence by providing the recognition for RNA polymerase and other factors
required for proper transcription. “Promoter” includes a minimal promoter that is a
short DNA sequence comprised of a TATA- box and other sequences that serve to
specify the site of transcription initiation, to which regulatory elements are added for
control of expression. “Promoter” also refers to a nucleotide sequence that includes
a minimal promoter plus regulatory elements that is capable of controlling the
expression of a coding sequence or functional RNA. This type of promoter
sequence consists of proximal and more distal upstream elements, the latter elements
often referred to as enhancers. Accordingly, an “enhancer” is a DNA sequence that
can stimulate promoter activity and may be an innate element of the promoter or a
heterologous element inserted to enhance the level or tissue specificity of a
promoter. It is capable of operating in both orientations (normal or flipped), and is
capable of functioning even when moved either upstream or downstream from the
promoter. Both enhancers and other upstream promoter elements bind sequence-
specific DNA-binding proteins that mediate their effects. Promoters may be derived
in their entirety from a native gene, or be composed of different elements derived
from different promoters found in nature, or even be comprised of synthetic DNA
segments. A promoter may also contain DNA sequences that are involved in the
binding of protein factors that control the effectiveness of transcription initiation in
response to physiological or developmental conditions. Examples of promoters that
may be used include the mouse U6 RNA promoters, synthetic human H1RNA
promoters, SV40, CMV, RSV, RNA polymerase II and RNA polymerase III
promoters.
The "initiation site" is the position surrounding the first nucleotide that is
part of the transcribed sequence, which is also defined as position +1. With respect
to this site all other sequences of the gene and its controlling regions are numbered.
Downstream sequences (i.e., further protein encoding sequences in the 3 ′ direction)
are denominated positive, while upstream sequences (mostly of the controlling
regions in the 5 ′ direction) are denominated negative.
Promoter elements, particularly a TATA element, that are inactive or that
have greatly reduced promoter activity in the absence of upstream activation are
referred to as "minimal or core promoters." In the presence of a suitable
transcription factor, the minimal promoter functions to permit transcription. A
“minimal or core promoter” thus consists only of all basal elements needed for
transcription initiation, e.g., a TATA box and/or an initiator.
“Constitutive expression” refers to expression using a constitutive or
regulated promoter. “Conditional” and “regulated expression” refer to expression
controlled by a regulated promoter.
“Operably-linked” refers to the association of nucleic acid sequences on
single nucleic acid fragment so that the function of one of the sequences is affected
by another. For example, a regulatory DNA sequence is said to be “operably linked
to” or “associated with” a DNA sequence that codes for an RNA or a polypeptide if
the two sequences are situated such that the regulatory DNA sequence affects
expression of the coding DNA sequence (i.e., that the coding sequence or functional
RNA is under the transcriptional control of the promoter). Coding sequences can be
operably-linked to regulatory sequences in sense or antisense orientation.
“Expression” refers to the transcription and/or translation of an endogenous
gene, heterologous gene or nucleic acid segment, or a transgene in cells. For
example, in the case of epitope constructs, expression may refer to the transcription
of the epitope only. In addition, expression refers to the transcription and stable
accumulation of sense (mRNA) or functional RNA. Expression may also refer to
the production of protein.
The term “transformation” refers to the transfer of a nucleic acid fragment
into the genome of a host cell, resulting in genetically stable inheritance. A “host
cell” is a cell that has been transformed, or is capable of transformation, by an
exogenous nucleic acid molecule. Host cells containing the transformed nucleic acid
fragments are referred to as “transgenic” cells.
“Transformed,” “transduced,” “transgenic” and “recombinant” refer to a
host cell into which a heterologous nucleic acid molecule has been introduced. As
used herein the term “transfection” refers to the delivery of DNA into eukaryotic
(e.g., mammalian) cells. The term “transformation” is used herein to refer to
delivery of DNA into prokaryotic (e.g., E. coli) cells. The term “transduction” is
used herein to refer to infecting cells with viral particles. The nucleic acid molecule
can be stably integrated into the genome generally known in the art. Known
methods of PCR include, but are not limited to, methods using paired primers,
nested primers, single specific primers, degenerate primers, gene-specific primers,
vector-specific primers, partially mismatched primers, and the like. For example,
"transformed," "transformant," and "transgenic" cells have been through the
transformation process and contain a foreign gene integrated into their chromosome.
The term "untransformed" refers to normal cells that have not been through the
transformation process.
“Genetically altered cells” denotes cells which have been modified by the
introduction of recombinant or heterologous nucleic acids (e.g., one or more DNA
constructs or their RNA counterparts) and further includes the progeny of such cells
which retain part or all of such genetic modification.
Nucleic Acid Molecules
The terms "isolated and/or purified" refer to in vitro isolation of a nucleic
acid, e.g., a DNA or RNA molecule from its natural cellular environment, and from
association with other components of the cell, such as nucleic acid or polypeptide,
so that it can be sequenced, replicated, and/or expressed. The RNA or DNA is
"isolated" in that it is free from at least one contaminating nucleic acid with which it
is normally associated in the natural source of the RNA or DNA and is preferably
substantially free of any other mammalian RNA or DNA. The phrase "free from at
least one contaminating source nucleic acid with which it is normally associated"
includes the case where the nucleic acid is reintroduced into the source or natural
cell but is in a different chromosomal location or is otherwise flanked by nucleic
acid sequences not normally found in the source cell, e.g., in a vector or plasmid.
As used herein, the term “recombinant nucleic acid”, e.g., “recombinant
DNA sequence or segment” refers to a nucleic acid, e.g., to DNA, that has been
derived or isolated from any appropriate cellular source, that may be subsequently
chemically altered in vitro, so that its sequence is not naturally occurring, or
corresponds to naturally occurring sequences that are not positioned as they would
be positioned in a genome which has not been transformed with exogenous DNA.
An example of preselected DNA “derived” from a source would be a DNA sequence
that is identified as a useful fragment within a given organism, and which is then
chemically synthesized in essentially pure form. An example of such DNA
"isolated" from a source would be a useful DNA sequence that is excised or
removed from a source by chemical means, e.g., by the use of restriction
endonucleases, so that it can be further manipulated, e.g., amplified, for use as
described herein, by the methodology of genetic engineering. "Recombinant DNA"
includes completely synthetic DNA sequences, semi synthetic DNA sequences,
DNA sequences isolated from biological sources, and DNA sequences derived from
RNA, as well as mixtures thereof.
Expression Cassettes
To prepare expression cassettes, the recombinant DNA sequence or segment
may be circular or linear, double-stranded or single-stranded. Generally, the DNA
sequence or segment is in the form of chimeric DNA, such as plasmid DNA or a
vector that can also contain coding regions flanked by control sequences that
promote the expression of the recombinant DNA present in the resultant transformed
cell.
A “chimeric” vector or expression cassette, as used herein, means a vector or
cassette including nucleic acid sequences from at least two different species, or has a
nucleic acid sequence from the same species that is linked or associated in a manner
that does not occur in the “native” or wild type of the species.
Aside from recombinant DNA sequences that serve as transcription units for
an RNA transcript, or portions thereof, a portion of the recombinant DNA may be
untranscribed, serving a regulatory or a structural function. For example, the
recombinant DNA may have a promoter that is active in mammalian cells.
Other elements functional in the host cells, such as introns, enhancers,
polyadenylation sequences and the like, may also be a part of the recombinant DNA.
Such elements may or may not be necessary for the function of the DNA, but may
provide improved expression of the DNA by affecting transcription, or the like.
Such elements may be included in the DNA as desired to obtain the optimal
performance of the RNA in the cell.
Control sequences are DNA sequences necessary for the expression of an
operably linked coding sequence in a particular host organism. The control
sequences that are suitable for prokaryotic cells, for example, include a promoter,
and optionally an operator sequence, and a ribosome binding site. Eukaryotic cells
are known to utilize promoters, polyadenylation signals, and enhancers.
Operably linked nucleic acids are nucleic acids placed in a functional
relationship with another nucleic acid sequence. For example, a promoter or
enhancer is operably linked to a coding sequence if it affects the transcription of the
sequence; or a ribosome binding site is operably linked to a coding sequence if it is
positioned so as to facilitate translation. Generally, operably linked DNA sequences
are DNA sequences that are linked are contiguous. However, enhancers do not have
to be contiguous. Linking is accomplished by ligation at convenient restriction sites.
If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used
in accord with conventional practice.
The recombinant DNA to be introduced into the cells may contain either a
selectable marker gene or a reporter gene or both to facilitate identification and
selection of expressing cells from the population of cells sought to be transfected or
infected through viral vectors. In other embodiments, the selectable marker may be
carried on a separate piece of DNA and used in a co-transfection procedure. Both
selectable markers and reporter genes may be flanked with appropriate regulatory
sequences to enable expression in the host cells. Useful selectable markers are
known in the art and include, for example, antibiotic-resistance genes, such as neo
and the like.
Reporter genes are used for identifying potentially transfected cells and for
evaluating the functionality of regulatory sequences. Reporter genes that encode for
easily assayable proteins are well known in the art. In general, a reporter gene is a
gene that is not present in or expressed by the recipient organism or tissue and that
encodes a protein whose expression is manifested by some easily detectable
property, e.g., enzymatic activity. For example, reporter genes include the
chloramphenicol acetyl transferase gene (cat) from Tn9 of E. coli and the luciferase
gene from firefly Photinus pyralis. Expression of the reporter gene is assayed at a
suitable time after the DNA has been introduced into the recipient cells.
The general methods for constructing recombinant DNA that can transfect
target cells are well known to those skilled in the art, and the same compositions and
methods of construction may be utilized to produce the DNA useful herein.
The recombinant DNA can be readily introduced into the host cells, e.g.,
mammalian, bacterial, yeast or insect cells by transfection with an expression vector
composed of DNA encoding the epitope or conjugated compound by any procedure
useful for the introduction into a particular cell, e.g., physical or biological methods,
to yield a cell having the recombinant DNA stably integrated into its genome or
existing as a episomal element, so that the DNA molecules, or sequences are
expressed by the host cell. Preferably, the DNA is introduced into host cells via a
vector. The host cell is preferably of eukaryotic origin, e.g., plant, mammalian,
insect, yeast or fungal sources, but host cells of non-eukaryotic origin may also be
employed.
Physical methods to introduce a preselected DNA into a host cell include
calcium phosphate precipitation, lipofection, particle bombardment, microinjection,
electroporation, and the like. Biological methods to introduce the DNA of interest
into a host cell include the use of DNA and RNA viral vectors. For mammalian
gene therapy, as described herein below, it is desirable to use an efficient means of
inserting a copy gene into the host genome. Viral vectors, and especially retroviral
vectors, have become the most widely used method for inserting genes into
mammalian, e.g., human cells. Other viral vectors can be derived from poxviruses,
herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like.
See, for example, U.S. Patent Nos. 5,350,674 and 5,585,362.
As discussed herein, a “transfected” “or “transduced” host cell or cell line is
one in which the genome has been altered or augmented by the presence of at least
one heterologous or recombinant nucleic acid sequence. The host cells as described
are typically produced by transfection with a DNA sequence in a plasmid expression
vector, a viral expression vector, or as an isolated linear DNA sequence. The
transfected DNA can become a chromosomally integrated recombinant DNA
sequence, which is composed of sequence encoding the epitope or conjugated
compound.
To confirm the presence of the recombinant DNA sequence in the host cell, a
variety of assays may be performed. Such assays include, for example, "molecular
biological" assays well known to those of skill in the art, such as Southern and
Northern blotting, RT-PCR and PCR; "biochemical" assays, such as detecting the
presence or absence of a particular peptide, e.g., by immunological means (ELISAs
and Western blots) or by assays described herein to identify agents falling within the
scope of the present description.
To detect and quantitate RNA produced from introduced recombinant DNA
segments, RT-PCR may be employed. In this application of PCR, it is first
necessary to reverse transcribe RNA into DNA, using enzymes such as reverse
transcriptase, and then through the use of conventional PCR techniques amplify the
DNA. In most instances PCR techniques, while useful, will not demonstrate
integrity of the RNA product. Further information about the nature of the RNA
product may be obtained by Northern blotting. This technique demonstrates the
presence of an RNA species and gives information about the integrity of that RNA.
The presence or absence of an RNA species can also be determined using dot or slot
blot Northern hybridizations. These techniques are modifications of Northern
blotting and only demonstrate the presence or absence of an RNA species.
While Southern blotting and PCR may be used to detect the recombinant
DNA segment in question, they do not provide information as to whether the
preselected DNA segment is being expressed. Expression may be evaluated by
specifically identifying the peptide products of the introduced recombinant DNA
sequences or evaluating the phenotypic changes brought about by the expression of
the introduced recombinant DNA segment in the host cell.
Methods for Introducing the Expression Cassettes into Cells
The nucleic acid material (e.g., an expression cassette encoding the epitope
or conjugated compound) can be introduced into the cell ex vivo or in vivo by
genetic transfer methods, such as transfection or transduction, to provide a
genetically modified cell. Various expression vectors (i.e., vehicles for facilitating
delivery of exogenous nucleic acid into a target cell) are known to one of ordinary
skill in the art.
As used herein, "transfection of cells" refers to the acquisition by a cell of
new nucleic acid material by incorporation of added DNA. Thus, transfection refers
to the insertion of nucleic acid into a cell using physical or chemical methods.
Several transfection techniques are known to those of ordinary skill in the art
including calcium phosphate DNA co-precipitation, DEAE-dextran, electroporation,
cationic liposome-mediated transfection, tungsten particle-facilitated microparticle
bombardment, and strontium phosphate DNA co-precipitation.
In contrast, "transduction of cells" refers to the process of transferring
nucleic acid into a cell using a DNA or RNA virus. A RNA virus (i.e., a retrovirus)
for transferring a nucleic acid into a cell is referred to herein as a transducing
chimeric retrovirus. Exogenous nucleic acid material contained within the retrovirus
is incorporated into the genome of the transduced cell. A cell that has been
transduced with a chimeric DNA virus (e.g., an adenovirus carrying a cDNA
encoding a therapeutic agent), will not have the exogenous nucleic acid material
incorporated into its genome but will be capable of expressing the exogenous
nucleic acid material that is retained extrachromosomally within the cell.
The exogenous nucleic acid material can include the nucleic acid encoding
the epitope or conjugated compound together with a promoter to control
transcription. The promoter characteristically has a specific nucleotide sequence
necessary to initiate transcription. The exogenous nucleic acid material may further
include additional sequences (i.e., enhancers) required to obtain the desired gene
transcription activity. For the purpose of this discussion an "enhancer" is simply any
non-translated DNA sequence that works with the coding sequence (in cis) to
change the basal transcription level dictated by the promoter. The exogenous
nucleic acid material may be introduced into the cell genome immediately
downstream from the promoter so that the promoter and coding sequence are
operatively linked so as to permit transcription of the coding sequence. An
expression vector can include an exogenous promoter element to control
transcription of the inserted exogenous gene. Such exogenous promoters include
both constitutive and regulatable promoters.
Naturally-occurring constitutive promoters control the expression of
essential cell functions. As a result, a nucleic acid sequence under the control of a
constitutive promoter is expressed under all conditions of cell growth. Constitutive
promoters include the promoters for the following genes which encode certain
constitutive or "housekeeping" functions: hypoxanthine phosphoribosyl transferase
(HPRT), dihydrofolate reductase (DHFR), adenosine deaminase, phosphoglycerol
kinase (PGK), pyruvate kinase, phosphoglycerol mutase, the beta-actin promoter,
and other constitutive promoters known to those of skill in the art. In addition,
many viral promoters function constitutively in eukaryotic cells. These include: the
early and late promoters of SV40; the long terminal repeats (LTRs) of Moloney
Leukemia Virus and other retroviruses; and the thymidine kinase promoter of
Herpes Simplex Virus, among many others.
Nucleic acid sequences that are under the control of regulatable promoters
are expressed only or to a greater or lesser degree in the presence of an inducing or
repressing agent, (e.g., transcription under control of the metallothionein promoter is
greatly increased in presence of certain metal ions). Regulatable promoters include
responsive elements (REs) that stimulate transcription when their inducing factors
are bound. For example, there are REs for serum factors, steroid hormones, retinoic
acid, cyclic AMP, and tetracycline and doxycycline. Promoters containing a
particular RE can be chosen in order to obtain a regulatable response and in some
cases, the RE itself may be attached to a different promoter, thereby conferring
regulatability to the encoded nucleic acid sequence. Thus, by selecting the
appropriate promoter (constitutive versus regulatable; strong versus weak), it is
possible to control both the existence and level of expression of a nucleic acid
sequence in the genetically modified cell. If the nucleic acid sequence is under the
control of an regulatable promoter, delivery of the therapeutic agent in situ is
triggered by exposing the genetically modified cell in situ to conditions for
permitting transcription of the nucleic acid sequence, e.g., by intraperitoneal
injection of specific inducers of the regulatable promoters which control
transcription of the agent. For example, in situ expression of a nucleic acid
sequence under the control of the metallothionein promoter in genetically modified
cells is enhanced by contacting the genetically modified cells with a solution
containing the appropriate (i.e., inducing) metal ions in situ.
Accordingly, the amount of RNA generated in situ is regulated by
controlling such factors as the nature of the promoter used to direct transcription of
the nucleic acid sequence, (i.e., whether the promoter is constitutive or regulatable,
strong or weak) and the number of copies of the exogenous nucleic acid sequence
encoding the epitope or conjugated compound sequence that are in the cell.
In addition to at least one promoter and at least one heterologous nucleic acid
sequence encoding the epitope or conjugated compound sequence, the expression
vector may include a selection gene, for example, a neomycin resistance gene, for
facilitating selection of cells that have been transfected or transduced with the
expression vector.
Cells can also be transfected with two or more expression vectors, at least
one vector containing the nucleic acid sequence(s) encoding the epitope or
conjugated compound sequence, the other vector containing a selection gene. The
selection of a suitable promoter, enhancer, selection gene, and/or signal sequence is
deemed to be within the scope of one of ordinary skill in the art without undue
experimentation.
The following discussion is directed to various utilities of the instant
invention and/or description. For example, the instant description has utility as an
expression system suitable for silencing the expression of gene(s) of interest.
Also described are methods for genetically modifying cells of a mammalian
recipient in vivo. According to one embodiment, the method comprises introducing
an expression vector for expressing the epitope or conjugated compound sequence in
cells of the mammalian recipient in situ by, for example, injecting the vector into the
recipient.
Formulations and Methods of Administration
The vaccines and compositions described may be formulated as
pharmaceutical compositions and administered to a mammalian host, such as a
human patient, in a variety of forms adapted to the chosen route of administration,
i.e., orally, intranasally, intradermally or parenterally, by intravenous, intramuscular,
topical or subcutaneous routes.
Thus, the present compounds may be systemically administered, e.g., orally,
in combination with a pharmaceutically acceptable vehicle such as an inert diluent
or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin
capsules, may be compressed into tablets, or may be incorporated directly with the
food of the patient's diet. For oral therapeutic administration, the active compound
may be combined with one or more excipients and used in the form of ingestible
tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the
like. Such compositions and preparations should contain at least 0.1% of active
compound. The percentage of the compositions and preparations may, of course, be
varied and may conveniently be between about 2 to about 60% of the weight of a
given unit dosage form. The amount of active compound in such therapeutically
useful compositions is such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like may also contain the
following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients
such as dicalcium phosphate; a disintegrating agent such as corn starch, potato
starch, alginic acid and the like; a lubricant such as magnesium stearate; and a
sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent
such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the
unit dosage form is a capsule, it may contain, in addition to materials of the above
type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other
materials may be present as coatings or to otherwise modify the physical form of the
solid unit dosage form. For instance, tablets, pills, or capsules may be coated with
gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active
compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as
preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any
material used in preparing any unit dosage form should be pharmaceutically
acceptable and substantially non-toxic in the amounts employed. In addition, the
active compound may be incorporated into sustained-release preparations and
devices.
The active compound may also be administered intravenously or
intraperitoneally by infusion or injection. Solutions of the active compound or its
salts may be prepared in water, optionally mixed with a nontoxic surfactant.
Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin,
and mixtures thereof and in oils. Under ordinary conditions of storage and use,
these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or infusion can
include sterile aqueous solutions or dispersions or sterile powders comprising the
active ingredient that are adapted for the extemporaneous preparation of sterile
injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
In all cases, the ultimate dosage form should be sterile, fluid and stable under the
conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent
or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for
example, glycerol, propylene glycol, liquid polyethylene glycols, and the like),
vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper
fluidity can be maintained, for example, by the formation of liposomes, by the
maintenance of the required particle size in the case of dispersions or by the use of
surfactants. The prevention of the action of microorganisms can be brought about
by various antibacterial and antifungal agents, for example, parabens, chlorobutanol,
phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to
include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged
absorption of the injectable compositions can be brought about by the use in the
compositions of agents delaying absorption, for example, aluminum monostearate
and gelatin.
Sterile injectable solutions are prepared by incorporating the active
compound in the required amount in the appropriate solvent with various of the
other ingredients enumerated above, as required, followed by filter sterilization. In
the case of sterile powders for the preparation of sterile injectable solutions, the
preferred methods of preparation are vacuum drying and the freeze drying
techniques, which yield a powder of the active ingredient plus any additional desired
ingredient present in the previously sterile-filtered solutions.
For topical administration, the present compounds may be applied in pure form, i.e.,
when they are liquids. However, it will generally be desirable to administer them to
the skin as compositions or formulations, in combination with a dermatologically
acceptable carrier, which may be a solid or a liquid.
Useful solid carriers include finely divided solids such as talc, clay,
microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include
water, alcohols or glycols or water-alcohol/glycol blends, in which the present
compounds can be dissolved or dispersed at effective levels, optionally with the aid
of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial
agents can be added to optimize the properties for a given use. The resultant liquid
compositions can be applied from absorbent pads, used to impregnate bandages and
other dressings, or sprayed onto the affected area using pump-type or aerosol
sprayers.
Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters,
fatty alcohols, modified celluloses or modified mineral materials can also be
employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and
the like, for application directly to the skin of the user.
Examples of useful dermatological compositions that can be used to deliver
the compounds of the present invention to the skin are known to the art; for
example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No.
4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No.
4,820,508).
Useful dosages of the compounds of the present invention can be determined
by comparing their in vitro activity, and in vivo activity in animal models. Methods
for the extrapolation of effective dosages in mice, and other animals, to humans are
known to the art; for example, see U.S. Pat. No. 4,938,949.
Generally, the concentration of the compound(s) of the present invention in a
liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably
from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition
such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.
The amount of the compound, or an active salt or derivative thereof, required
for use in treatment will vary not only with the particular salt selected but also with
the route of administration, the nature of the condition being treated and the age and
condition of the patient and will be ultimately at the discretion of the attendant
physician or clinician.
In general, however, a suitable dose will be in the range of from about 0.5 to
about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day,
such as 3 to about 50 mg per kilogram body weight of the recipient per day,
preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to
60 mg/kg/day.
The compound is conveniently administered in unit dosage form; for
example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently,
50 to 500 mg of active ingredient per unit dosage form.
Ideally, the active ingredient should be administered to achieve peak plasma
concentrations of the active compound of from about 0.5 to about 75 μM,
preferably, about 1 to 50 μM, most preferably, about 2 to about 30 μM. This may be
achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the
active ingredient, optionally in saline, or orally administered as a bolus containing
about 1-100 mg of the active ingredient. Desirable blood levels may be maintained
by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent
infusions containing about 0.4-15 mg/kg of the active ingredient(s).
The desired dose may conveniently be presented in a single dose or as
divided doses administered at appropriate intervals, for example, as two, three, four
or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a
number of discrete loosely spaced administrations; such as multiple inhalations from
an insufflator or by application of a plurality of drops into the eye.
Although the foregoing specification and examples fully disclose and enable
the present invention, they are not intended to limit the scope of the invention, which
is defined by the claims appended hereto.
All publications, patents and patent applications are incorporated herein by
reference. While in the foregoing specification this invention has been described in
relation to certain embodiments thereof, and many details have been set forth for
purposes of illustration, it will be apparent to those skilled in the art that the
invention is susceptible to additional embodiments and that certain of the details
described herein may be varied considerably without departing from the basic
principles of the invention.
In this specification where reference has been made to patent specifications,
other external documents, or other sources of information, this is generally for the
purpose of providing a context for discussing the features of the invention. Unless
specifically stated otherwise, reference to such external documents is not to be
construed as an admission that such documents, or such sources of information, in
any jurisdiction, are prior art, or form part of the common general knowledge in the
art.
The use of the terms “a” and “an” and “the” and similar referents in the
context of describing the invention are to be construed to cover both the singular and
the plural, unless otherwise indicated herein or clearly contradicted by context. The
terms “comprising,” “having,” “including,” and “containing” are to be construed as
open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise
noted. Recitation of ranges of values herein are merely intended to serve as a
shorthand method of referring individually to each separate value falling within the
range, unless otherwise indicated herein, and each separate value is incorporated
into the specification as if it were individually recited herein. All methods described
herein can be performed in any suitable order unless otherwise indicated herein or
otherwise clearly contradicted by context. The use of any and all examples, or
exemplary language (e.g., “such as”) provided herein, is intended merely to better
illuminate the invention and does not pose a limitation on the scope of the invention
unless otherwise claimed. No language in the specification should be construed as
indicating any non-claimed element as essential to the practice of the invention.
Embodiments of this invention are described herein, including the best mode
known to the inventors for carrying out the invention. Variations of those
embodiments may become apparent to those of ordinary skill in the art upon reading
the foregoing description. The inventors expect skilled artisans to employ such
variations as appropriate, and the inventors intend for the invention to be practiced
otherwise than as specifically described herein. Accordingly, this invention includes
all modifications and equivalents of the subject matter recited in the claims
appended hereto as permitted by applicable law. Moreover, any combination of the
above-described elements in all possible variations thereof is encompassed by the
invention unless otherwise indicated herein or otherwise clearly contradicted by
context.
Claims (31)
1. A compound comprising at least one antigen directly covalently bound to an antibody-recognition epitope (ARE), wherein the ARE is a VP-1 epitope of polio virus of about 11-28 amino acids in length comprising IPALTAVETGA (SEQ ID NO: 1).
2. The compound of claim 1, wherein the antigen is bound to the ARE by means of an alpha-Gal linkage.
3. The compound of claim 1, wherein the antigen is bound to the ARE by means of linker molecule.
4. The compound of claim 3, wherein the linker molecule is formaldehyde, gluteraldehyde, MBS (m-Maleimidobenzoyl-N-hydroxysuccinimide ester) and/or Sulfo-MBS.
5. The compound of any one of claims 1-4, wherein the antigen is an infectious agent antigen.
6. The compound of claim 5, wherein the infectious agent is a bacterial, fungal, parasitic, viral, or prion agent.
7. The compound of claim 6, wherein the infectious agent is a bacterial agent.
8. The compound of claim 6, wherein the infectious agent is a viral agent.
9. The compound of claim any one of claims 1-4, wherein the antigen is a cancer antigen.
10. The compound of any one of claims 1-9, wherein the antigen is further bound to an antibody to form an antibody:antigen complex.
11. The compound of claim 10, wherein the antibody is a human antibody or a humanized antibody.
12. The compound of claim 11, wherein the antibody is a humanized antibody.
13. The compound of claim 12, wherein the antibody is a fully humanized antibody.
14. The compound of claim 10, wherein the antibody is a single-chain Fv or an scFv fragment.
15. The compound of any one of claims 1-14, wherein a hapten is operably linked to the antigen to form a haptenated antigen.
16. The compound of claim 15, wherein the hapten is operably linked to a further antigen.
17. A complex comprising the compound of any one of claims 1-16 operably linked to a conjugation molecule.
18. The complex of claim 17, wherein the conjugation molecule is a peptide, a nucleic acid, or a polysaccharide that is not the antigen or ARE.
19. A composition comprising the compound of any one of claims 1-16 or the complex of claim 17 or 18 and a physiologically-acceptable, non-toxic vehicle.
20. The composition of claim 19, further comprising an adjuvant.
21. Use of the compound of any one of claims 1-16, or the complex of claim 17 or claim 18, in the manufacture of a medicament for eliciting an immune response in a pre-immunized animal.
22. The use of claim 21, wherein the medicament is to be administered at least 15 days after the pre-immunization.
23. The use of claim 21 or 22, wherein the medicament is for administration with a composition of claim 19 or 20.
24. The use of any one of claims 21-23, wherein a repeat dose of the medicament is to be administered.
25. The use of any one of claims 21-24, wherein the animal is a human.
26. Use of the compound of any one of claims 1-16, or the complex of claim 17 or claim 18, in the manufacture of a medicament for generating antibodies specific for an antigen in a pre-immunized animal.
27. Use of the compound of any one of claims 1-16, or the complex of claim 17 or claim 18, in the manufacture of a medicament for treating cancer.
28. Use of the compound of any one of claims 1-16, or the complex of claim 17 or claim 18, in the manufacture of a medicament for preventing or treating an infection or infectious disease.
29. A compound comprising at least one purified antigen directly covalently bound to an antibody-recognition epitope (ARE), wherein the ARE is the VP-1 epitope of a VP-1 epitope of polio virus of about 11-28 amino acids in length comprising IPALTAVETGA (SEQ ID NO: 1), for use in the prophylactic or therapeutic treatment of an infectious agent or cancer.
30. A compound comprising at least one purified antigen directly covalently bound to an antibody-recognition epitope (ARE), wherein the ARE is the VP-1 epitope of a VP-1 epitope of polio virus of about 11-28 amino acids in length comprising IPALTAVETGA (SEQ ID NO: 1), for the manufacture of a medicament useful for the treatment of an infectious agent or cancer in a mammal.
31. A compound comprising at least one antigen covalently bound to an antibody-recognition epitope (ARE), wherein the antigen is Nucleocapsid Protein (NP) from Influenza A H5N1 (A/Indonesia/
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161471553P | 2011-04-04 | 2011-04-04 | |
US61/471,553 | 2011-04-04 | ||
PCT/US2012/032190 WO2012138774A2 (en) | 2011-04-04 | 2012-04-04 | Methods of improving vaccine immunogenicity |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ617303A NZ617303A (en) | 2016-07-29 |
NZ617303B2 true NZ617303B2 (en) | 2016-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017218957A1 (en) | Methods of improving vaccine immunogenicity | |
AU2016225926A1 (en) | Methods of improving vaccine immunogenicity | |
SA96170384B1 (en) | Methods of preparation and therapeutic uses (RSV) Human neutralizing monoclonal antibodies with high affinity for the F-protein of respiratory syncytial virus | |
US11826408B2 (en) | CD200 inhibitors and methods of use thereof | |
JP2016531934A (en) | Influenza vaccine and treatment | |
JP2011502163A (en) | Combination therapies to treat persistent viral infections | |
JP2001516583A (en) | Peptide derived from RS virus attachment (G) protein | |
US20230372466A1 (en) | Universal mammalian influenza vaccine | |
US6838553B1 (en) | Peptide repeat immunogens | |
KR20020073149A (en) | Nucleic acid vaccination | |
NZ617303B2 (en) | Methods of improving vaccine immunogenicity | |
US10092635B2 (en) | Tumor vaccines and methods of use thereof | |
Kruglov et al. | Inactivated whole virion vaccine protects K18‐hACE2 Tg mice against the Omicron SARS‐CoV‐2 variant via cross‐reactive T cells and nonneutralizing antibody responses | |
TWI398262B (en) | Immunogenic peptides of tumor associated antigen l6 and uses thereof in cancer therapy |